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Abstract
Antigen presentation by major histocompatibility complex class II (MHC II) to the
adaptive immune system is crucial for mounting sterilizing immune responses. This
central role has made antigen presentation a target for antagonism by many pathogens.
Notably, infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
decrease MHC II expression in several immune cells. The mechanisms responsible for
this suppression are unknown but involves either redirecting MHC II molecules away
from the cell surface or inhibiting MHC II expression. To understand how pathogens
manipulate intracellular MHC II trafficking, we first investigated the role of the Golgi
trafficking regulator, ERC1, in this pathway, which we have previously confirmed is
necessary for phagosome maturation. Immunofluorescence microscopy demonstrated that
ERC1 facilitates the recruitment of MHC II to phagosomes, thereby enabling antigen
loading and presentation. Interestingly, SARS-CoV-2 non-structural protein 5 (NSP5)
interacts with histone deacetylase 2 (HDAC2)—a regulator of MHC II transcription—
suggesting that SARS-CoV-2 may antagonize antigen presentation through epigenetic
reprogramming. We hypothesize that SARS-CoV-2 NSP5 downregulates MHC II
expression via interactions with HDAC2. RT-qPCR and dual luciferase analyses
demonstrated that NSP5 expression was sufficient to downregulate MHC II in primary
human dendritic cells and RAW 264.7 macrophages. HDAC2 knockdown alleviated this
suppression, indicating that NSP5 utilizes host histone deacetylation machinery to
antagonize MHC II transcription. Unexpectedly, point mutations that inactivate the
catalytic site of NSP5 failed to revert this phenotype, suggesting that the proteolytic
ability of NSP5 is not required for this suppression. This research may identify an
important mechanism used by SARS-CoV-2 to evade adaptive immune responses and
may indicate a potential use of HDAC2 inhibitors as therapeutics against coronavirus
disease 19 (COVID-19).
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Summary for Lay Audience
Every day we constantly encounter germs that can damage our bodies and cause
debilitating diseases should they continue to persist. Our immune system fights off
against infections through several ways. Particularly, specialized immune cells called
phagocytes can eat microbes and break these microbes down into small pieces called
antigens that are displayed on an MHC II molecule to communicate with other immune
cells. To hide from the immune system, bacteria and viruses try to impair this process,
either by decreasing MHC II levels or preventing MHC II from reaching the organelle
where antigens reside. Surprisingly, it is unclear how MHC II is delivered to the antigencontaining organelle; hence, it is unknown how pathogens block this process. We
discovered a protein called ERC1 that acts like a magnet by attracting MHC II to the
antigen-containing organelle and allowing antigens to be presented to other immune cells.
Interestingly, the virus responsible for COVID-19—SARS-CoV-2—interacts with
components involved in controlling MHC II expression, suggesting that this virus targets
these proteins to block MHC II from displaying antigens. We found that one of the viral
proteins expressed by SARS-CoV-2, NSP5, can target another protein called HDAC2 to
decrease MHC II levels in various immune cell types. In addition, modifying cells such
that they no longer express HDAC2 restored MHC II levels. Together, these experiments
help us better understand the functions of our immune system and how pathogens can
persist in our bodies, such is the case in COVID-19. Using this information, it may be
possible to develop better treatments to combat against COVID-19 and finally put an end
to the pandemic.

Keywords
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Chapter 1
INTRODUCTION
1.1 Antigen Presentation on MHC II
Professional antigen presenting cells (pAPCs), such as macrophages and dendritic cells
(DCs), are pivotal in alerting the adaptive immune system to the presence of invading
pathogens. Specifically, pAPCs present pathogen-derived antigens to T cells to mount an
adaptive immune response—a process heavily mediated by major histocompatibility
complex (MHC) molecules1,2.
Two major classes of MHC molecules are expressed in human cells: MHC I is present on
all nucleated cells and is required for presenting endogenous antigens to CD8+ T cells,
while MHC II is expressed by pAPCs and specific non-pAPCs, such as endothelial and
epithelial cells, and is responsible for presenting exogenous peptides to CD4+ T cells.
MHC II is a cell-surface protein composed of polymorphic α and β chains containing a
transmembrane region and two extracellular immunoglobulin domains3. These chains are
assembled by chaperones in the endoplasmic reticulum (ER) where they associate with
the invariant chain (CD74) that prevents inappropriate loading of endogenous antigens
and induction of autoimmune disorders4–7. The MHC II-CD74 complex traffics through
the Golgi and into a Golgi-derived vesicle where it is subsequently transported to the
phagosome, and CD74 is degraded into a short peptide, known as class II-associated
invariant chain peptide (CLIP), which acts as a placeholder prior to peptide loading8.
Here, HLA-DM mediates the removal and exchange of CLIP with a pathogen-derived
peptide onto MHC II9. This MHC II-peptide complex is then exported to the cell surface

2

to be presented to a CD4+ T cell to initiate adaptive immune responses against the target
pathogen10.
While the importance of MHC II in antigen presentation is well established, it is critical
to understand the mechanisms that regulate MHC II expression and trafficking to their
necessary locations to ensure that adaptive immune responses are properly initiated.
Antigen presentation on MHC II is dependent on two regulatory processes: MHC II
transcription and MHC II trafficking.

1.2 CIITA and HDAC2 are Major Regulators of MHC II
Transcription
Transcription of MHC II genes is controlled at several levels (Figure 1). Notably, a
highly conserved cis-regulatory sequence (W-X1-X2-Y box) located directly upstream of
the MHC II transcriptional start site plays an important role in this process11. These
regulatory elements are bound by the transcription factors RFX5, CREB, and NF-Y,
leading to the formation of a transcriptionally inactive, combinatorial DNA-protein
complex. Binding of the class II transactivator (CIITA) protein to this complex forms the
MHC II enhanceosome, activating MHC II expression12. An additional enhancer region is
found several kilobases 5' to this region, with a similar W-X1-X2-Y box structure that
may be required to initiate transcription of MHC II genes13.
CIITA is considered the master regulator of interferon gamma (IFNγ)-induced
transcription of MHC II genes, thereby playing a crucial role in generating adaptive
immune responses against pathogens. Deficient levels of CIITA have been linked to
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downregulation of MHC II, leading to severe autoimmune diseases such as type II bare
lymphocyte syndrome14. CIITA-mediated MHC II transcription is dependent on IFNγ
receptor (IFNγR) binding to its target ligand, initiating a downstream signaling pathway
that leads to phosphorylation and homodimerization of STAT1, enabling its entry into the
nucleus. Nuclear STAT1 then activates IRF1, and together, they induce expression of
CIITA. While not binding directly to the W-X1-X2-Y enhancer elements, CIITA
functions by forming a transcriptionally active complex with transcription factors bound
to those enhancer elements, where it coordinates the recruitment of additional regulatory
proteins.

Notably,

enhanceosome-bound

CIITA

recruits

multiple

histone

acetyltransferases (HATs), such as CBP and PCAF, to the MHC II promoter to activate
transcription15,16. CIITA itself also possesses intrinsic acetyltransferase activity, allowing
for direct induction of MHC II transcription17.
CIITA can also function as a negative regulator through recruitment of histone
deacetylases (HDACs) that silence MHC II transcription. HDACs regulate many cellular
processes through the removal of acetyl groups from N-terminal lysine residues on core
histones, thereby playing a crucial role in repressing expression of multiple genes18,19.
This reversible process is opposed by HATs that acetylate histones, thereby increasing
the accessibility of chromatin by DNA-binding proteins and activating gene expression20.
HDACs are classified into four distinct classes based on size and function, consisting of
Class I, Class IIa, Class IIb, Class III, and Class IV. HDAC2—a Class I HDAC—is a
transcriptional and functional regulator of CIITA and MHC II through various
modifications21,22. Specifically, HDAC2 inhibits transcription of CIITA and MHC II
through histone deacetylation on the promoter regions23,24. Likewise, chromatin
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immunoprecipitation studies demonstrated that HDAC2 prevents recruitment of CIITA to
RFX5, thereby repressing activation of MHC II transcription22. Lastly, CIITA is also
marked for degradation by the proteasome through interactions with HDAC2. Treatment
with HDAC2 inhibitors have been identified to ameliorate this downregulation of CIITA
expression and activity24, suggesting a potential opportunity in targeting HDAC2 to
restore MHC II and CIITA expression in patients suffering from impaired adaptive
immune responses.
In addition to post-translational modifications, CIITA expression is regulated at the level
of transcription in a cell type- and cytokine-dependent manner. Three different CIITA
isoforms, each containing a unique first exon, can be generated depending on which
promoter is used25. CIITA promoter I (pI) drives expression in myeloid cells such as DCs
and macrophages stimulated with IFNγ, pIII drives expression in lymphoid cells
including B cells and human activated CD4+ T cells, and pIV drives expression in IFNγstimulated non-hematopoietic cells.

5

Figure 1. Regulation of MHC II transcription.
Transcription of MHC II genes is controlled through a highly conserved regulatory
sequence (W-X1-X2-Y box) located directly upstream of the transcriptional start site.
This module is bound by transcription factors RFX5, CREB, and NF-Y, forming a
transcriptionally inactive DNA-protein complex. IFNγ receptor activation initiates a
signaling cascade that induces expression of CIITA, enabling its recruitment to the
complex and activating MHC II transcription. HDAC2 serves as a negative regulator of
CIITA and MHC II transcription through histone deacetylation at the promoters. Figure
prepared in BioRender.
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1.3 Proper MHC II Trafficking is Crucial for Antigen
Presentation
Another form of MHC II regulation is the trafficking of this protein to an appropriate
destination, such as the phagosome for antigen loading or to the cell surface for antigen
presentation. While it is well established that many pathogens can obscure their detection
by hijacking host cell machinery and manipulating intracellular MHC II trafficking, it has
remained controversial for over twenty years how newly synthesized MHC II molecules
are delivered to phagosomes8,26. As such, before exploring the mechanisms by which
pathogens alter the vesicular trafficking pathways responsible for initiating antigen
presentation, it is crucial to understand how MHC II is transported to the phagosome for
proper peptide loading.
The peptide-loading process for MHC II is well understood, starting with pAPCs
sampling the extracellular environment and encountering an extracellular pathogen which
is recognized by surface receptors and engulfed through phagocytosis. Following
engulfment, the internalized pathogen is fully contained within a plasma membranederived vacuole termed the phagosome. The phagosome undergoes a series of highly
regulated biochemical modifications to efficiently degrade the internalized pathogen in a
remodeling process called phagosome maturation. This process is characterized both by
sequential fusion with early and late endosomes along with progressive acidification of
the phagosomal lumen to drive the breakdown of phagocytic cargo. Phagosome
maturation is driven by the sequential recruitment of the small GTPases Rab5 and Rab7
to the phagosome surface. Following closure of the phagocytic cup, Rab5 is recruited to
the site of phagocytosis where it mediates the fusion between the phagosome and early
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endosomes. Rab5 is subsequently replaced by Rab7, marking the transition to the late
endosome which undergoes gradual acidification and fusion with lysosomes to form the
phagolysosome27. Upon acquisition of lysosome-derived enzymes, internalized pathogens
are killed and degraded into short antigenic peptides. Phagosome-derived Toll-like
receptor (TLR) signaling then initiates the fusion between phagolysosomes with
incoming MHC II-containing vesicles, thereby forming the MHC II loading compartment
(MIIC) where peptide loading occurs28. This MHC II-peptide complex is subsequently
exported to cell surface, allowing the peptide to be presented to CD4+ T cells to initiate
adaptive immune responses against the phagocytosed pathogen.

1.4 Two Potential Vesicular Trafficking Pathways Dictate
the Formation of the MIIC
While the importance of antigen processing and presentation in generating sterilizing
immune responses are well established, it remains controversial how newly synthesized
MHC II molecules are transported from the Golgi to the MIIC, with two putative
trafficking pathways speculated to be responsible for this delivery (Figure 2).

1.4.1 Indirect Endolysosomal Trafficking Pathway
The antigen presentation field favours a trafficking model where unloaded MHC II-CD74
complexes are released from the Golgi and exported to the cell surface via the
constitutive secretion pathway, followed by re-internalization by clathrin-mediated
endocytosis and delivery to the MIIC through endolysosomal trafficking29,30. This model
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is based primarily on the detection of MHC II and CD74 on the plasma membranes of
pAPCs, as well as high rates of surface MHC II endocytosis31–34. In vitro studies
identified two dileucine-based signals in the CD74 cytoplasmic domain involved in
directing MHC II molecules to the cell surface and to endocytic compartments35.
Specifically, these signals bind to adaptor protein (AP) complexes, AP-1 and AP-2,
which are components of clathrin coats involved in vesicle formation and cargo sorting36.
While the mechanisms by which these proteins are involved in directing MHC II
trafficking are unclear, RNA silencing of AP-2—a major regulator of transport between
the plasma membrane and early endosomes—impairs the transport of CD74 to
endosomal vesicles, committing CD74 to remain on the cell surface37. As AP-2 is solely
associated with the plasma membrane, this finding supports the role of clathrin-mediated
endocytosis in the indirect route of MHC II-CD74 trafficking38. While these findings
suggest that MHC II utilizes an indirect endolysosomal trafficking pathway, there are
several flaws with this model. Critically, unloaded cell-surface MHC II molecules have
not been observed to traffic from the cell surface through Rab5- and Rab7-decorated
endosomes, despite studies claiming passage through these compartments being a
requisite step in the delivery of MHC II to MIICs39. Likewise, recent studies
demonstrated that CD74 trafficking does not correspond directly with MHC II transport,
with these two molecules being observed to passage through separate intracellular
compartments upon LPS stimulation in mature DCs40. Specifically, CD74 is often
detected on the cell surface in the absence of newly synthesized MHC II, and vice versa,
suggesting that the presence of this complex on the cell surface is coincidental and may
not be indicative of unloaded MHC II undergoing cellular export41–43. As such, despite
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CD74 appearing on the cell surface and possessing AP-2-interacting motifs conducive of
clathrin-mediated endocytosis, the evidence supporting the indirect endolysosomal route
for MHC II trafficking are weak.

1.4.2 Direct Golgi-to-MIIC Trafficking Pathway
Given the aforementioned limitations, some groups have postulated that an alternative
pathway may be responsible for trafficking MHC II to the MIIC. Specifically, MHC II
may be transported by vesicles from the Golgi directly to the MIIC, independent of its
exocytosis and re-internalization44,45. Indeed, some studies observed that MHC II and
CD74 are transported directly from the trans-Golgi network towards the MIIC45–47.
However, as with the studies proposing the indirect endolysosomal route, there is a lack
of evidence demonstrating that MHC II transports through pathways known to deliver
Golgi-derived proteins to intracellular organelles45. While not previously implicated in
the delivery of MHC II to the MIIC, most organelles receive proteins directly from the
Golgi through a Rab6-mediated Golgi export pathway48–50. This pathway was previously
shown to deliver Golgi-derived cargo to other lysosome-derived organelles. For example,
in melanocytes, Rab6 delivers melanin synthesis enzymes from the Golgi directly to
lysosome-derived melanosomes, with the Rab6 effector protein ERC1 on melanosomes
acting as a docking site for Rab6-bearing vesicles51. Published work by our lab used
magnetic isolation and mass spectrometry to identify the presence of MHC II, Rab6, and
components of the Rab6 docking complex, including ERC1, on the membranes of
phagosomes from human primary macrophages52. Furthermore, ERC1 was observed to
be recruited to phagosomes, and ERC1 knockdown using shRNA delayed the recruitment
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of MHC II to the phagosome and abrogated the formation of MIICs (data not shown). As
MIICs are also lysosome-derived organelles, these findings suggest that Rab6 and ERC1
are responsible for delivering MHC II to this compartment via a direct Golgi export
pathway.
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Figure 2. Putative vesicular trafficking pathways of MHC II.
Upon phagocytosis, newly synthesized MHC II molecules may be delivered from the
Golgi to the site of antigen acquisition via two possible pathways: 1) initial export to the
plasma membrane followed by clathrin-mediated endocytosis and endolysosomal
trafficking to the MIIC (pink), or 2) direct Golgi-to-MIIC transport (green). Figure
prepared in BioRender.
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1.5 Role of Rab GTPases in Regulating MHC II Trafficking
Rab GTPases are monomeric proteins that function as master regulators of vesicular
trafficking by directing the movement and fusion of vesicles with other cellular
compartments53. While typically in its inactive state when bound by GDP, Rabs are
activated by GTP exchange factors which mediate the exchange of GDP for GTP54. Once
activated, Rabs regulate intracellular trafficking by enabling the budding and targeting of
transport vesicles and their cargo from donor to specific acceptor compartments54,55. Rabs
possess intrinsic GTPase activity that mediate their self-inactivation via removal of a
terminal phosphate from their bound GTP, thus converting to an inactive GDP-bound
state. This activity is induced by interactions with GTPase activating proteins56. Within
the human genome, there are over 70 Rabs involved in the transport of specific
intracellular compartments and vesicles, thereby providing specificity to cellular
trafficking pathways55. As previously mentioned, Rabs and their effector proteins are
likely involved in the vesicular trafficking of MHC II from the Golgi to MIICs.
Currently, two vesicular trafficking pathways have been described to facilitate this
process, each utilizing different Rab GTPases.
The indirect endolysosomal trafficking pathway would require a secretory or exocytic
pathway to mediate the export of MHC II from the Golgi to the cell surface, as well as
endosomal regulators that deliver surface MHC II to the MIIC. Three Rab GTPases have
been described to regulate trafficking of secretory vesicles from the Golgi to the plasma
membrane—Rab3a, Rab8, and Rab2757–59. While not reported to be involved in MHC II
trafficking, these proteins modulate exocytosis by interacting directly with secretory
vesicles and granules in multiple cell types, with Rab3a observed to localize proximal to
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plasma membranes60. Rab5 is the most well-characterized regulator of endocytic
trafficking, where it is primarily found in clathrin-coated endocytic vesicles and early
endosomes, playing a role in receptor-mediated endocytosis and early endosome
biogenesis61. Lastly, Rab7 is a regulator of the fusion of early endocytic vesicles with late
endosomes and lysosomes62. Altogether, we speculate that should MHC II utilize the
indirect endolysosomal route, it likely involves the sequential actions of exocytic
trafficking regulators (e.g. Rab3) to initially export MHC II-CD74 to the cell surface,
Rab5 to mediate endocytosis and formation of the early endosome, and Rab7 to facilitate
endolysosomal trafficking to the MIIC. In contrast, an alternative pathway has been
described wherein MHC II is directly transported from the Golgi to the MIIC. Rab6 is the
major regulator of vesicular budding from the Golgi network in both anterograde and
retrograde directions, and it has been implicated in the delivery of proteins directly to
lysosome-derived organelles49,51,63. Rab6 was also observed to regulate the transport of
secretory vesicles to ERC1-decorated plasma membranes, suggesting that it may be
involved in the indirect endolysosomal trafficking pathway64. However, previous findings
from our lab and the literature suggest that Rab6 and ERC1 are responsible for
facilitating the direct Golgi-to-MIIC trafficking pathway.

1.6 ERC1 Potentially Regulates Expression and Trafficking
of MHC II Through the Canonical TLR-Mediated NFκB
Activation Pathway
ERC1 is a 128 kDa, multifaceted, globular, coiled-coil protein that is ubiquitously
expressed in the cytosol65. It contains a coiled Rab-binding domain at its C-terminus that
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mediates interactions with Rab6. ERC1 is central to the canonical nuclear factor kappa B
(NFκB) activation pathway. Typically, inactive NFκB is sequestered in the cytosol
through the masking of its nuclear localization signal by the inhibitor IκBα66. Release of
NFκB requires phosphorylation of IκBα by the IκB kinase (IKK) complex, which is
composed of three subunits: the kinase domain (α and β) and the regulatory domain (γ,
NEMO)67. TLR signaling can initiate a signaling cascade that results in phosphorylation
and activation of NEMO, subsequently leading to IKK-mediated phosphorylation of IκBα
and nuclear translocation of NFκB68. NFκB family members then modulate the
expression of several genes, including MHC II and other pro-inflammatory cytokines that
can exacerbate inflammatory responses and tissue damage should their expression exceed
normal levels69,70. As such, it is important that NFκB translocation and activation is
tightly controlled. ERC1 is known to be activated downstream of TLR signaling and is a
critical component of the IKK complex, where its absence has been linked to delayed
phosphorylation of IκBα and, consequently, cytosolic sequestration of NFκB in its
inactive state71. The exact mechanisms by which ERC1 controls phosphorylation of IκBα
remain unclear, but studies have implicated ERC1 to function as a bridging molecule by
facilitating the recruitment of NEMO to the α and β subunits and enabling
phosphorylation of the IKK complex by upstream kinases72.
As phagosomes bear functional TLRs, which are known to be activated by the detection
of pathogen-derived molecules, it is suggested that phagocytosis can initiate a signaling
cascade that releases ERC1 from the IKK complex, enabling its deposition onto the
phagosome membrane. Based on previous findings from our lab, phagosome-bound
ERC1 then facilitates the vesicular trafficking of Golgi-secreted proteins directly to the

15

phagosome through interactions with Rab6, thereby forming an MIIC upon delivery of
MHC II.

1.7 Antigen Presentation and CD4+ T Cell Responses are
Impaired in Patients with COVID-19
Presentation of antigens on MHC II to CD4+ T cells is a crucial step in initiating
sterilizing immune responses against pathogens. This central role has made antigen
presentation a prime target for antagonism by many pathogens to prevent successful
generation of adaptive immunity, either by suppressing MHC II transcription or
redirecting MHC II away from the cell surface. One such example is the virus responsible
for causing coronavirus disease 2019 (COVID-19).
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
in late 2019, the ongoing COVID-19 pandemic has garnered international attention and
has taken the lives of over 6 million people worldwide, making infections with this
deadly virus one of the leading causes of morbidity and mortality, overtaken only by
heart diseases and cancer73. While human infections with coronaviruses is not unheard of,
as we have seen regular zoonotic transmission of coronaviruses to humans over the past
20 years, including the original SARS-CoV outbreak in the early 2000s and repeated
outbreaks of Middle Eastern respiratory syndrome coronavirus (MERS-CoV) starting in
2012, it remains poorly understood how infections with these likely bat-originated
coronaviruses result in high lethality in humans74. Notably, patients with COVID-19 have
been observed to suffer from T cell exhaustion and short-lived humoral immunity, with
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reduced MHC II expression and antigen presentation to CD4+ T cells speculated to be
underlying causes. How SARS-CoV-2 downregulates MHC II remains to be elucidated.

1.8 SARS-CoV-2 Structure and Genome
Coronaviruses are members of the Coronaviridae family and are enveloped viruses with
a positive-sense single-stranded RNA genome ranging from 26 to 32 kb in size75. SARSCoV-2 is closely related to SARS-CoV and MERS-CoV, and it expresses 29 viral
proteins, consisting of 16 non-structural proteins (NSP1-16), 4 structural proteins
(Spike/S, Envelope/E, Matrix/M, Nucleocapsid/N), and 9 accessory factors (ORF3a-b, 6,
7a-b, 8, 9b-c, and 10). Many of these viral proteins are capable of interfering with host
immune systems through various mechanisms76. Notably, ORF6 limits antiviral cytokine
responses by preventing nuclear translocation of STAT1 and suppressing type I IFN
signaling pathways, whereas ORF8 reduces activation of CD8+ cytotoxic T cells by
selectively directing MHC I molecules to lysosomes where they are degraded77,78.

1.9 Infection of Dendritic Cells and Macrophages by SARSCoV-2
Coronaviruses infect human cells through interactions between envelope-anchored S
glycoprotein with host angiotensin-converting enzyme 2 (ACE2) receptors. S-protein
consists of two subunits: an ACE2 receptor-binding domain (S1) and a domain that
drives viral and host cell membrane fusion (S2)79. Viral entry occurs upon host
transmembrane serine protease 2 (TMPRSS2)-mediated cleavage of S-protein80,81.
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SARS-CoV-2 may also enter host cells via clathrin-mediated endocytosis, allowing entry
into endosomes, and subsequent fusion between viral and endolysosomal membranes
upon cleavage of S protein by endosomal cysteine protease cathepsin L82,83.
While it is well established that the ACE2 receptor is required for coronavirus infection
of human cells, SARS-CoV-2 can infect and activate lung-tissue resident DCs despite
these cells lacking ACE284–87. Several studies have implicated that S protein may interact
with TLRs to active immune responses88–90. However, exposure of DCs to S protein and
SARS-CoV-2 virus particles does not lead to TLR4 activation; rather, ACE2-expressing
DCs were shown to be infected and activated by SARS-CoV-2 infections, suggesting that
intracellular viral sensors are necessary for detecting and responding to SARS-CoV-291.
While this observation explains how DCs can be activated by SARS-CoV-2, it remains
poorly understood how they can be infected in the first place. It is speculated that DCs
uptake SARS-CoV-2 virions by engulfing infected ACE2-expressing cells to initiate
antigen processing and presentation to CD4+ T cells. However, once internalized, the
acidic environment of the phagosome favours membrane fusion rather than delivery of
viruses to the lysosome for degradation92–95. Ultimately, SARS-CoV-2 can escape the
phagosomes of DCs and enter host cytosol, leading to viral replication and assembly87,96.
As such, despite lacking ACE2 expression, DCs can be infected indirectly via engulfment
of the virions themselves or of SARS-CoV-2-infected cells. Macrophages, on the other
hand, express ACE2 and are therefore conducive to direct infections by SARS-CoV-2.
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1.10 SARS-CoV-2 Antagonizes Antigen Presentation
Through an Unknown Mechanism
It is well known that human coronaviruses can impair antigen presentation on MHC II.
For example, infections with MERS-CoV—a closely related member to SARS-CoV-2—
have been observed to downregulate MHC II and MHC I expression in pAPCs, thereby
suppressing CD4+ and CD8+ T cell responses97,98. Additionally, patients with severe
COVID-19 have decreased levels of MHC I and MHC II in several immune cells,
including monocytes, DCs, and B cells, and in vitro infections with SARS-CoV-2
reduced surface MHC II expression in human macrophages99–101. Despite the importance
of antigen presentation in initiating the defense responses necessary for controlling
SARS-CoV-2 infections, it remains unknown how this virus can impair this process to
escape immunosurveillance. While it was recently discovered that SARS-CoV-2 ORF6
may potentially reduce MHC I expression, the specific viral proteins responsible for
suppressing MHC II expression have not been identified102.
A common strategy utilized by pathogens to prevent antigen presentation is redirecting
MHC molecules away from the cell surface, thereby limiting the generation of CD4+ T
cell responses. For example, the HIV Nef prevents antigen presentation by trafficking
MHC I molecules away from the cell surface and towards a Golgi-proximal organelle103.
In addition to redirection of surface MHC molecules, pathogens may also suppress MHC
II expression. For example, other human coronaviruses, such as MERS-CoV, have been
shown to epigenetically reprogram the host transcriptional machineries in infected cells,
thereby reducing MHC II levels97,104. Indeed, a recent interactome analysis of SARSCoV-2 identified viral non-structural protein 5 (NSP5) as an interactor of HDAC2—an
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epigenetic regulator of CIITA and MHC II transcription—albeit the effects of NSP5 on
HDAC2 activity are unknown105. NSP13 was also identified to target multiple
components of Golgi trafficking pathways, including ERC1, suggesting that SARS-CoV2 may also block antigen presentation through manipulating the direct Golgi-tophagosome trafficking route for MHC II, thus impairing MIIC formation. However, the
focus of this thesis is the investigation of SARS-CoV-2 NSP5 in altering MHC II
expression.

1.11 SARS-CoV-2 NSP5 Potentially Suppresses MHC II
Expression
NSP5 is one of two cysteine proteases expressed by SARS-CoV-2. It plays a critical role
in viral infection by proteolytically cleaving the SARS-CoV-2 polyprotein into individual
NSPs, subsequently leading to viral replication and assembly106. Self-cleavage at the Nand C-terminals of NSP5 is also an important processing step for proper function. This
central role in viral replication makes NSP5 an interesting and viable drug target, as
malfunctions and deletions of NSP5 have been shown to decrease virus viability and
reduce ensuing inflammatory responses107–109.
Outside of its role in viral replication, it is speculated that NSP5 from other coronaviruses
can cleave host proteins to disrupt molecular pathways and host immune responses110.
Recent studies implicated NSP5 as a multifaceted protein that functions in interfering
with multiple antiviral response pathways to assist in viral propagation. For example,
NSP5 impairs antiviral responses through multiple mechanisms, including antagonism of
RIG-I and MAVS, as well as prevention of IRF3 nuclear translocation to suppress
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expression of IFN-stimulated genes111. Likewise, NSP5 enhances expression of proinflammatory cytokines, including IL-6, IL-1B, TNFα, and IL-2, through activation of
the NFκB pathway, possibly attributing to the excessive inflammatory responses and
cytokine storms observed in patients with COVID-19112,113. Most intriguingly, NSP5 was
recently identified to interact with HDAC2, suggesting a possibility to directly impair
MHC II expression and prevent activation of CD4+ T cells necessary to clear
infections105.

1.12 Hypothesis and Aims
In this thesis, I addressed two hypotheses. Firstly, I hypothesized that MIICs are formed
via a Rab6/ERC1-dependent trafficking pathway which directly transports MHC II from
the Golgi to the phagosome. Secondly, I hypothesized that SARS-CoV-2 NSP5
downregulates MHC II expression via interactions with HDAC2.
Aim 1: Develop the tools necessary to detect MHC II trafficking and expression and
determine how MHC II is delivered to phagosomes.
Aim 2: Assess the effects of SARS-CoV-2 NSP5 on MHC II expression and antigen
presentation.
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Chapter 2

2

Materials and Methods

2.1 Materials
HeLa cells were gifts from Dr. Stephen Barr (University of Western Ontario, London,
Canada). HEK293T cells were gifts from Dr. Sergio Grinstein (Hospital for Sick
Children, Toronto, Canada). RAW 264.7 and J774A.1 murine macrophages were
purchased from ATCC (Manassas, Virginia). Roswell Park Memorial Institute (RPMI),
Dulbecco’s Modified Eagle Medium (DMEM), and Fetal Bovine Serum (FBS) were
purchased

from

Wisent

(Saint-Jean-Baptise,

Canada).

Trypsin-EDTA

and

antibiotic/antimycotic were purchased from Corning (Manassas, Virginia). #1.5 thickness
8-mm round coverslips and 16 % paraformaldehyde (PFA) were purchased from Electron
Microscopy Supplies (Hatfield, Pennsylvania). GenJet Plus, DNA isolation kits, and all
lab plasticware were purchased from Frogga Bio (Concord, Canada). All laboratory
chemicals were purchased from Bioshop Canada (Burlington, Canada). WGAAlexaFluor 647, Hoechst, Permafluor mounting reagent, FuGene HD, and HALT
protease/phosphatase inhibitors, were purchased from Thermo Fisher Canada
(Mississauga, Canada). Phusion DNA polymerase, all restriction enzymes, HiFi Gibson
Assembly Kit, Monarch Nucleic Acid Preparation Kit, and T4 DNA ligase were
purchased from NEB Canada (Whitby, Canada). Retro-X Universal Packaging System
was purchased from Takara Bio (San Jose, California). Recombinant human GM-CSF,
IFNγ, and IL-4 were purchased from Peprotech (Cranbury, New Jersey). iScript Select
cDNA Synthesis Kit, SsoFast EvaGreen Supermix, Instagene, and all protein blotting
reagents and gels were purchased from Bio-Rad Canada (Mississauga, Canada).
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Lympholyte-poly was purchased from Cedarlane Laboratories (Burlington, Canada). Cell
Proliferation Dye eFluor 670 was purchased from eBioscience (San Diego, California).
Polybrene Infection Reagent and ivermectin were purchased from EMD Millipore Corp
(Norwood, Ohio). Dual-Luciferase Reporter Assay System, and Janelia Fluor HaloTag
Ligands 549 and 646 were purchased from Promega (Madison, Wisconsin). RNeasy Mini
Kit was purchased from Qiagen (Germantown, Maryland). CD14 Positive Cell Selection
Kit and anti-DYKDDDDK tag (L5) were purchased from BioLegend (San Diego,
Calfornia). Polystyrene/divinylbenzene (PS/DVB) microsphere beads were purchased
from Bangs Laboratories (Fishers, Indiana). Lipofectamine 3000 and Lipofectamine LTX
transfection reagents were purchased from Life Technologies (Carlsbad, California).
Escherichia coli DH5α and ML35 strains were gifts from Drs. John McCormick and
Susan Koval, respectively (Western University, London, Canada).

2.2 Plasmids and Oligos
GalT-mCherry, KDEL-GFP, Rab5-GFP, and Rab7-mCherry expression constructs were
gifts from Dr. Sergio Grinstein (Hospital for Sick Children, Toronto, Canada). EGFPRab3A (Plasmid #49542), EGFP-Rab8 (Plasmid #49543), and EGFP-Rab27 (Plasmid
#49605)

expression

constructs

were

purchased

from

Addgene

(Watertown,

Massachusetts). pLVX-IRES-zsGreen lentiviral vector and pCMV-zsGreen packaging
vector were gifts from Dr. Jimmy Dikeakos (Western University, London, Canada).
pGL4.20 [luc/Puro] was purchased from Promega (Madison, Wisconsin). pRetroX-Tet3G
and pRetroX-TRE3G were purchased from Takara Bio (San Jose, California). The renilla
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luciferase internal control vector pRL-TK was a gift from Dr. Rodney DeKoter (Western
University, London, Canada). Accell SMARTpool non-targeting siRNA, HDAC2targeting siRNA, siRNA delivery media, and siRNA buffer were purchased from Horizon
Discovery (Cambridge, United Kingdom). All DNA primers, oligos, and synthesized
genes were purchased from IDT (Coralville, Iowa), and the sequences for all primers
used in this study can be found in Tables 1-2.

2.3 Culturing and Transfection of Cell Lines
HeLa cells, and RAW 264.7 and J774A.1 murine macrophages were maintained in
DMEM supplemented with 10 % FBS. Cells were split at 80 % confluency by washing
once with phosphate buffered saline (PBS: 0.9 % NaCl, 10 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4) followed by a 5 min incubation in trypsin-EDTA at 37 °C and
resuspension in DMEM + 10 % FBS. For imaging, HeLa cells were seeded into 12-well
tissue culture plates with #1.5 thickness 18 mm diameter coverslips, 1 mL of DMEM +
10 % FBS added, and 100 µL of cell suspension added dropwise to each well. After
overnight incubation, cells were transfected with the desired DNA construct according to
manufacturer’s protocol. Briefly, for each well, two tubes of 38 µL serum-free DMEM
were prepared. Then, 3 µL of GenJet Plus was added to one tube and 1 µg of DNA was
added to the second tube. Diluted GenJet Plus reagent was added to the diluted DNA
solution. Following a brief vortex, the mixture was incubated for 10-15 min at room
temperature to allow the DNA:GenJet Plus complexes to form. Finally, the mixture was
added dropwise to the desired well and incubated for 18-24 h at 37 °C. For ivermectin
treatment, 25 µM of ivermectin or DMSO were added to cells for 90 min at 37 °C.
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RAW 264.7 macrophages were transfected using Neon electroporation as per
manufacturer’s instructions. Briefly, 1 x 106 cells/well were collected in 1.5 mL tubes and
centrifuged at 400 xg for 5 min, followed by resuspension in 1 mL of PBS. Cells were
centrifuged again at 400 xg for 5 min, and supernatant was removed afterwards. Each
sample was then resuspended in 5 µg of DNA and an appropriate volume of R buffer.
Samples were then transferred to a Neon electroporation apparatus and shocked using the
following conditions: 1680 V, 20 ms pulse width, and 1 pulse. Following transfection,
cells were allowed to recover for 20 min in a new PCR tube. Cells were then transferred
to a 12-well plate and incubated at 37 °C.
J774A.1 macrophages were transfected using the FuGene method. 2.5 x 105 cells were
seeded into 12-well tissue culture plates on #1.5 thickness 18 mm diameter coverslips
with 1 mL of DMEM + 10 % FBS added. DNA was prepared according to
manufacturer’s instructions. Briefly, to each well to be transfected, 150 µL of serum-free
DMEM was added to a sterile 1.5 mL microfuge tube, to which a total of 3.3 µg of the
desired DNA construct(s) were added. After a brief vortex to mix the contents, 10 µL of
FuGene HD transfection reagent was added to the tube followed by mixing the DNAreagent solution. The mixture was allowed to incubate for 15 mins at room temperature
before being added dropwise to the desired well and incubated for 18-24 h at 37 °C to
allow for cell recovery and transgene expression.
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2.4 Culturing and Transduction of Human Primary Dendritic
Cells
Primary human dendritic cells were prepared from monocytes isolated from whole blood
isolated from healthy adult donors with ethics approval from the Office of Human
Research Ethics at Western University Health Sciences Research Ethics Boards and
performed in accordance with the guidelines of the Tri-Council policy statement on
human research. Blood was collected through venipuncture into vacuum tubes coated
with heparin, and monocytes were isolated using Lympholyte-poly separation media
according to manufacturer’s instructions. Briefly, approximately 4 mL of blood was
layered over an equal volume of Lympholye-poly and centrifuged for 25 min at 500 ×g at
50 % acceleration and zero deceleration. The mononuclear cell layer was carefully
removed using a transfer pipette to a clean 50 mL tube and resuspended in 50 mL of PBS
and subsequently centrifuged for 6 min at 300 ×g at full acceleration and deceleration.
Peripheral blood mononuclear cells (PBMCs) were resuspended in 200 µL of warm
RPMI for each well of a 12-well plate. Sterile, acid-washed glass coverslips (2 M HCl,
overnight at 55 °C) were placed into 12-well plates and the PBMC suspension was
transferred onto coverslips. Cells were incubated for 2 h at 37 °C + 5 % CO2 to allow
monocytes to adhere to glass. Coverslips were washed 3× with PBS to remove nonadherent cells. Cells were maintained in culture with RPMI supplemented with 10 %
FBS, L-glutamine and sodium bicarbonate, 10,000 U/mL penicillin, 10 mg/mL
streptomycin, 25 µg/ml amphotericin B, and buffered with 25 mM HEPES to pH 7.2. To
generate dendritic cells, adherent monocytes were additionally supplemented with 1000
U/mL rhGM-CSF and 500 U/mL rhIL-4 for 48 h, with culture media replenished with
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fresh complete RPMI supplemented with 1000 U/mL rhGM-CSF and 500 U/mL rhIL-4
for an additional 48 h.
Primary DCs were transduced with NSP5-expressing or empty pLVX-zsGreen lentiviral
vectors. Briefly, cells were plated on 48-well tissue culture plates and infected at a
multiplicity of infection (MOI) of 30, followed by centrifugation at 500 ×g for 90 min at
32 °C. Plates were then transferred to a 37 °C + 5 % CO2 incubator for 8 h, at which
point cells were supplemented with fresh warm media and allowed to incubate for an
additional 72 h. For IFNγ stimulation, 10 ng/mL of recombinant human IFNγ was added
for 24 h to induce MHC II expression. For siRNA treatment, 5 nmol of HDAC2- and
non-targeting siRNA were resuspended in 50 µL of 1x siRNA buffer (300 mM KCl, 30
mM HEPES-pH 7.5, 1.0 mM MgCl2) to obtain a 100 µM stock solution. 2 µM of siRNA
resuspended in siRNA delivery media were added to the cells, followed by incubation at
37 °C + 5 % CO2 for 72 h.

2.5 Molecular Cloning
Recombinant expression vectors were prepared through restriction enzyme digestion and
subsequent ligation of appropriate insert sequences and vector backbones. Briefly, a
DNA insert consisting of the consensus coding sequence of the gene of interest was
amplified using standard PCR with primers designed to add flanking restriction enzyme
sites compatible with the multiple cloning site of the vector backbone. A list of all PCR
primers used for cloning can be found in Table 1. PCR reactions were run for 30 cycles
with Phusion DNA polymerase according to manufacturer’s instructions. Subsequently,
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the insert and backbone were digested with appropriate restriction enzymes for 1 h at 37
°C and gel purified using 1% agarose gel and the Monarch Nucleic Acid Preparation Kit
according to manufacturer’s instructions. Purified cut insert and backbone were ligated at
a ratio of 10:1 insert to backbone overnight at 16 °C with 20,000 U/mL T4 ligase.
Ligated vectors were transformed into chemically competent Escherichia coli DH5α cells
by heat shock for 2 min at 42 °C. Transformed E. coli were plated on LB agar
supplemented with the appropriate selective antibiotic and incubated overnight at 37 °C.
Single colonies appearing following incubation were propagated in liquid LB media
overnight at 37 °C and shaking at 200 RPM. Following overnight incubation, plasmids
were harvested from cultures using the High-Speed Plasmid Mini Kit according to
manufacturer’s instructions. Correct insertion of insert into backbone was confirmed by
Sanger sequencing at the Robarts Research Institute.

2.5.1 MHC II-HaloTag Cloning
A gene block comprised of HLA-DRB1 with a short GS linker to HaloTag and HLADRA was cloned into a pRetroX-TRE3G vector by Gibson assembly. CD74-MHC IIHaloTag was generated by amplifying two fragments of the original MHC II-HaloTag
vector using PCR, followed by Gibson assembly to clone a CD74 gene block into the
MHC II-HaloTag vector. Amplicons were then circularized with T4 DNA ligase. Vector
maps for MHC II-HaloTag cloning are available on Appendix A.

28

2.5.2 Dual Luciferase Cloning
MHC II and CIITA (pI and pIV) promoters were amplified from human DNA via PCR
using primers from Table 1. After amplification, promoters were cloned into pGL4.2
luciferase reporter vectors by Gibson assembly, and amplicons were circularized with T4
DNA ligase. Vector maps for dual luciferase cloning are available on Appendix B.

2.5.3 NSP5 Cloning
Briefly, FLAG-tagged NSP5 was cloned into an EcoRI-digested pLVX-puro lentiviral
vector, and untagged NSP5 was cloned into a pLVX-zsGreen lentiviral vector by Gibson
assembly. Point mutants were generated by amplifying the entirety of the original NSP5FLAG vector with phosphorylated primers that incorporate the point mutation in the first
base pair of the forward primer, while deletion mutants were generated by amplifying the
vector from either side of the desired deletion with phosphorylated primers. Following
amplification, the parental plasmid was removed by DpnI digestion, and the amplicons
were circularized with T4 DNA ligase. Vector maps for NSP5 cloning are available on
Appendix C.

2.6 Immunofluorescence Microscopy
2.6.1 Immunostaining
Cells to be stained were grown on 18 mm, #1.5 thickness round coverslips placed into the
wells of a 12-well tissue culture plate. If necessary, cells were stained with wheat germ
agglutinin (WGA) for 10 min at 10 °C and rinsed 3× with PBS. Otherwise, cells were
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equilibrated to room temperature to prevent membrane turnover and subsequently washed
1× with PBS. Cells were fixed with 4 % PFA for 20 min at room temperature and
subsequently washed with PBS to remove excess PFA. Fixed cells were blocked and
permeabilized with blocking buffer (0.1 % Triton X-100, 2.5 % bovine serum albumin
(BSA)) in PBS. Blocking buffer was removed, and primary antibody in 2.5 % BSA was
added to cells and allowed to incubate for 1 h at room temperature. Cells were washed 3×
10 min. Secondary antibodies in 2.5 % BSA was added to cells and allowed to incubate
for 1 h at room temperature. Cells were washed 3 × 10 min and incubated in 1:10000
Hoechst in PBS for 5 min. Cell-containing coverslips were mounted onto glass slides
using Permafluor mounting reagent and stored at 4 °C until imaging.

2.6.2 Fluorescence Imaging
Microscopy was used to visualize cell morphology and perform quantification of
fluorescence intensity. In all cases, at least three technical replicates were analyzed. For
measurement of fluorescence within individual cells, a minimum of 30 cells were
quantified. To minimize observer bias, random fields of view were captured whenever
possible. Imaging of stained cells was performed using a Leica DMI6000B
epifluorescence microscope equipped with a photometrics Evolve-512 delta EM-CCD
camera (Teledyne Photometrics), and a Sedat Quad filter set (Chroma) operated by Leica
LAS-X software. If necessary, z-sections were captured for phagocytosis assays and
colocalization experiments across the entire depth of the phagocyte separated by at least
0.25 µm between stacks.
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2.6.3 Image Analysis
All image analyses were performed using the FIJI distribution of ImageJ, unless
otherwise stated114,115. Measurements of fluorescence intensity was performed by forming
a selection around the region of interest (ROI) and using the “Measure” feature to obtain
the area and integrated density of the ROI. Background fluorescence was measured using
a region free of any cells or other features and was subtracted from the integrated density
of each ROI.

2.7 MHC II-HaloTag Expression System
2.7.1 Preparation of IgG-Coated Phagocytic Targets
Whole IgG-coated beads were prepared according to our lab’s published methods116.
Briefly, 10 µL of 3.17 µm PS/DVB microsphere beads were mixed with 1 mL of PBS in
a 1.5 mL microfuge tube, followed by centrifugation at 5000 ×g for 1 min. Supernatant
was removed and beads were resuspended in 100 µL of PBS and 10 µL of whole rat IgG.
Tubes were rotated for 90 min at room temperature. Afterwards, beads were washed
twice and resuspended with 100 µL of PBS.

2.7.2 Phagocytosis Assay
Phagocytosis assays were carried out according to our lab’s previously published
methods116. J774A.1 macrophages were grown on #1.5 thickness 18 mm round glass
coverslips on a 12-well plate. Following overnight incubation, cells were transfected with
Rab5-GFP and Rab7-mCherry according to Section 2.3.
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For live cell imaging, cells were transferred to a heated and CO2-perfused Leiden
chamber, filled with an appropriate volume of warm media, attached to the piezoelectric
stage of a Leica DMI6000B epifluorescence microscope. 10 µL of suspended IgG-coated
beads were added into the Leiden chamber and mixed carefully using a pipette. Images
were captured at 4-min intervals up to a duration of 2 h. Between 5-10 cells of interest
were marked using the Mark and Find feature of the Leica LAS-X software.
For fixed cell imaging, cells were allowed to equilibrate to room temperature to prevent
premature target uptake. The desired number of phagocytic targets were added into each
well, and the mixture was centrifuged for 1 min at 500 g to force contact between
phagocytes and phagocytic targets. Plates were then incubated at various time points at
37 °C, followed by fixation using 4 % PFA and staining with Hoechst. If necessary, cells
were stained with the appropriate primary and species-specific secondary antibodies
according to Section 2.6.1. Finally, cell-containing coverslips were mounted onto glass
slides and imaged using an epifluorescence microscope. A minimum of 30 macrophages
were counted for each condition.

2.8 Quantitative Reverse Transcription PCR (RT-qPCR)
2.8.1 RNA Preparation
Total RNA was isolated from THP-1 cells or primary DCs using RNeasy Mini Kit (BioRad) according to manufacturer’s instructions. Cells were harvested as a pellet and
homogenized in 350 µL of Buffer RLT. An equal volume of 70 % ethanol was added to
cell lysate. Samples were transferred to an RNeasy Mini spin column placed in a 2 mL
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collection tube and centrifuged for 15 s at 8000 ×g. 700 µL of Buffer RW1 was added to
the spin column, and samples were centrifuged for 15 s at 8000 ×g. 500 µL of Buffer
RPE was added to the spin column, and samples were centrifuged for 15 s at 8000 ×g.
This step was repeated once more after flowthrough was discarded. Spin columns were
transferred to a new 1.5 mL collection tube, and 50 µL of RNase-free water was added.
Samples were centrifuged for 1 min at 8000 ×g to elute the RNA. Total RNA
concentration and quality were measured using a NanoDrop 1000 Spectrophotometer
prior to cDNA preparation.

2.8.2 cDNA Preparation and RT-qPCR
cDNA was generated from total RNA using the iScript Select cDNA Synthesis Kit (BioRad) according to manufacturer’s instructions, with an equal amount of starting RNA and
equal mix of the oligo(dT)20 primer mixes. RT-qPCR was performed using the SsoFast
EvaGreen Supermix with an equal amount of starting cDNA. All RT-qPCR primers used
in this thesis can be found in Table 2. RT-qPCR reactions were run on a QuantStudio 3
Real-Time PCR System (Thermo Fisher) for 40 amplification cycles.

Relative

expression of genes of interest was calculated using the following ΔΔCt method with
GAPDH serving as the reference gene:
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2.9 Dual Luciferase Assay
Dual luciferase assays were performed using a Dual-Luciferase Reporter Assay System
according to manufacturer’s instructions to measure MHC II and CIITA promoter
activity in response to NSP5 expression. RAW 264.7 macrophages and HeLa cells were
co-transfected with NSP5-FLAG, the internal renilla luciferase control vector pRL-TK,
and either a pGL4.20-MHC II, pGL4.20-CIITA pI, or pGL4.20-CIITA pIV firefly
luciferase reporter vector using the Neon electroporation method according to Section
2.3. At 72 h post-transfection, cells were lysed using passive lysis buffer for 15 min, with
agitation. Lysed cells were transferred to a 1.5 mL Eppendorf tube and centrifuged at
max speed for 1 min. Equal volumes of supernatant (50 µL) were transferred to a 96-well
white plate in duplicates. 25 µL of Luciferase Assay Reagent II (LAR II) was added to
each well, and Firefly luciferase (FLuc) expression was measured using a Cytation 5
luminometer. 50 µL of Stop and Glo 1X reagent was added to quench the LAR II, and
Renilla luciferase (RLuc) expression was measured. Promoter activity was calculated
using the following equation:

2.10 Western Blot
Western blotting was employed to detect proteins of interest in cultured cells. 1 x 106
HeLa cells were cultured and transfected with appropriate DNA. Cells were washed in
PBS and incubated for 72 h to allow protein detection prior to lysis. Cellular lysis was
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performed using RIPA (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS, and 50 mM pH 8.0 Tris-HCl). Appropriate lysis buffer containing 1:100 v/v
mammalian protease and phosphatase inhibitors were added to cells, followed by
scraping cells into suspension. Lysate was immediately transferred to a clean 1.5 mL tube
and boiled for 5 min. Denatured cell lysates were run on a 10 % SDS-PAGE gel for 60
min at 120 V or until the leading edge of the lysates have nearly reached the bottom of
the gel. Proteins were transferred to a nitrocellulose membrane overnight at 40 V at 4 °C.
Following transfer, membranes were washed 1× with Tris-buffered saline + 0.1% Tween
(TBS-T) prior to processing. Membranes were blocked with 5% BSA blocking buffer in
TBS-T for a minimum of 2 h at room temperature with gentle agitation. Primary
antibodies were added to blocking buffer at an appropriate concentration and allowed to
incubate for 1 h at room temperature. Membranes were washed 3 × with TBS-T and
incubated in blocking buffer with an appropriate concentration of infrared dye-conjugated
secondary antibodies added. Membranes were allowed to incubate for 1 h at room
temperature with gentle agitation. Subsequently, membranes were washed 3 × with TBST and imaged on an Odyssey CLx Imaging System (LI-COR).

2.11 Generation of Phylogenetic Trees
Amino acid sequences of HDAC2 from various vertebrate species were retrieved from
the NCBI BLASTp database. Amino acid sequences of NSP5 across four coronavirus
genera were retrieved in a similar manner. Amino acid alignments of HDAC2 and NSP5
sequences were imported into MEGA11, and coding sequence alignments were generated
with MUSCLE using default parameters117. Pairwise distances were calculated using a
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Poisson model assuming uniform rates across sites, and maximum likelihood trees were
generated using a 500-iteration bootstrapping approach. Phylogenetic trees were then
generated to explore the evolutionary relationship of each protein across multiple species.

2.12 Statistical Analysis
All statistical analyses were performed on GraphPad Prism 9 software. Comparisons
between two means/medians made use of a Mann-Whitney test, while comparisons
between multiple means made use of a Kruskal-Wallis test.

36

Table 1. Cloning primer sequences used in this study
Primer

Sequence
Dual luciferase cloning primers

CIITA pI

F: 5'-AGCTCGCTAGCCTCGAGGATGATATTGGCAGCTGGCACCA-3'
R: 5'-CGCCGAGGCCAGATCTTGATCAGCTCAGAAGCACACAGCC-3'

CIITA pIV

F:5'-AGCTCGCTAGCCTCGAGGATTGCCACTTCTGATAAAGCACGTGG-3'
R: 5'-CGCCGAGGCCAGATCTTGATGGCAGCTCGTCCGCTGGTCA-3'

MHC II
Promoter

F: 5'-AGCTCGCTAGCCTCGAGGATTCCGTGATTGACTAACAGTC-3'
R: 5'-CGCCGAGGCCAGATCTTGATGAATAAAAGAAAAGAGAATGTGGG-3'

Luciferase
Split

5'-AACTGGCCGGTACCTGAGC-3'
5'-AGGCCAGAGAAATGTTCTGGCAC-3'
MHC II-HaloTag cloning primers

CD74

F: 5'-TCTTATACTTGGATCCATCGATACGCGTG-3'
R: 5'-CTCCAGGGAACTTCAGACACACCA-3'

MHC II

F: 5'-AACACTTTTGTCTTATACTTGGATCCATCGATACG-3'
R: 5'-CTCCAGGGAACTTCAGACACACCA-3'

pRetroXTre3G Split

F: 5'-TCGACCCTAGAGAACCATCAGATGTTC-3'
R: 5'-GAAACATCTGATGGTTCTCTAGGGTCGA-3'

MHC II
Polycistronic

F: 5'-ATGGTGTGTCTGAAGTTCCCTGG-3'
R: 5'-GCACGCGTATCGATGGATCC-3'
NSP5 cloning primers

NSP5-FLAG

F: 5'-CCGACTCTACTAGAGGATCTATTTCCGGT-3'
R: 5'-CGGCCGCTCTAGAACTAGTCTCG-3'

NSP5H41A

F: 5'- CTGTGATCTGCACCTCTGAAGACATGC -3'
R: 5'- CTCTTGGACAGTAAACTACGTCATCAAGCCA -3'

NSP5C145S

F: 5'- CTGGTAGTGTTGGTTTTAACATAGATTATGACTGTGT-3'
R: 5'- ATGAACCATTAAGGAATGAACCCTTAATAGTGAAATTG -3'

NSP5Δ1-192

F: 5'- GCAGCTGGTACGGACACAACTATTAC-3'
R: 5'- CATGAATTCACCGGAAATAGATCCTCTAGTAGAG-3'

NSP5Δ199-306

F: 5'- GCATCACCGGTAGACTACAAGGACC-3'
R: 5'- TGTGTCCGTACCAGCTGCTTG-3’
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Chapter 3

3

Results – Development of Tools to Detect MHC II
Trafficking and Expression

3.1 Development of MHC II-HaloTag Construct
To enable studies of MHC II trafficking, I first needed to design a technique to enable the
observation of MHC II movement in live cells, and in a manner that would allow its
expression to be controlled. Moreover, a method was required which would allow for
MHC II trafficking to be monitored shortly after its synthesis in the ER through to its
delivery to the MIIC. Fluorescent MHC II reporter transgenes were not viable options as
they are constitutively expressed, and the maturation time of most fluorescent proteins
lack the speed (>30 min) to enable visualization of newly synthesized MHC II
molecules118. Further complicating matters is the need to express the alpha (HLA-DRA)
and beta (HLA-DRB) chains of MHC II, along with CD74, to ensure proper formation of
the MHC II-CD74 complex. As such, I generated a doxycycline-inducible expression
system comprised of a CD74-HLA-DRB-HaloTag-HLA-DRA fusion protein containing
T2A self-cleaving peptide motifs between each protein, ensuring this protein will be
cleaved into individual CD74, HLA-DRB-HaloTag, and HLA-DRA proteins during
translation at a 1:1 stoichiometry. This reporter construct is normally turned off; however,
with the addition of a second regulatory Tet3G vector and doxycycline, I can induce
expression of Tet3G which subsequently binds to response elements on the promoter of
the MHC II-HaloTag construct, thereby allowing for inducible expression of MHC II.
The MHC II reporter itself is fused to a HaloTag that can be labeled with fluorescent
ligands, allowing for visualization of MHC II synthesis and trafficking on a fluorescence
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microscope, with labeling occurring within minutes of HaloTag ligand addition, thereby
enabling the ability to monitor protein trafficking immediately after translation into the
ER119.
This system was validated by co-transfecting HEK 293T cells with the MHC II-HaloTag
reporter and Tet3G regulatory constructs, followed by staining of MHC II and
immunofluorescence microscopy to confirm that fluorescently labeled HaloTag is
indicative of MHC II expression (Figure 3A). This system was further optimized by
determining the optimal doses for doxycycline and HaloTag ligand that would provide a
detectable MHC II signal under a fluorescence microscope. Serial dilutions of the
fluorescent HaloTag ligand demonstrated that a 40 nM dose maximized signal without
adding background or wasting reagent (Figure 3B). Furthermore, dose response
experiments were performed using serial dilutions of doxycycline prior to HaloTag
labeling, where I determined that 500 ng of doxycycline is an ideal concentration to
induce expression of MHC II-HaloTag without apparent expression artifacts, such as the
formation of large intracellular inclusions of the fluorescent protein (Figure 3C). In a
parallel experiment, I determined that the optimal time that induced the highest
expression of MHC II-HaloTag is 30 min post-treatment with doxycycline (Figure 3D).
Altogether, these experiments provided the framework and conditions required for
monitoring MHC II trafficking in more relevant cell types, such as macrophages and
DCs, in future experiments.
A)
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B)

D)
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Figure 3. Determining the optimal concentrations and incubations of HaloTag
ligand and doxycycline to induce MHC II-HaloTag expression.
HEK 293T cells were co-transfected with Tet3G and MHC II-HaloTag constructs. A)
Validation of doxycycline-inducible MHC II-HaloTag system via immunofluorescence
microscopy showing near-perfect overlap of the HaloTagged MHC II (red) and
immunostaining of MHC II (green). B) Cells were labeled with various concentrations of
HaloTag ligands following overnight incubation of 500 ng/mL doxycycline. C) Cells
were stimulated overnight with various concentrations of doxycycline, followed by
labeling with 40 nM of HaloTag ligand. D) Cells were stimulated with doxycycline at
various time points, followed by HaloTag labeling. Z-stacks were captured using
immunofluorescence microscopy, with image analyses to quantify integrated density
(IntDen) of MHC II-HaloTag. Data are presented as mean intensity of total MHC IIHaloTag expressed in cells for each condition and was obtained from one independent
experiment (n = 1). Scale bar is 10 µm.
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3.2 Monitoring Protein Trafficking Dynamics in
Macrophages
IgG-opsonized beads were used as pathogen mimics to perform phagocytosis assays in
J774A.1 macrophages co-expressing Rab5-GFP and Rab7-mCherry. While these beads
cannot be degraded by macrophages, their large size allows for detection by DIC
microscopy and enables accurate detection and quantification of fluorescent markers
recruited to phagosomes, thereby making them an ideal phagocytic target for the
purposes of this thesis. To demonstrate the utility of this model, I demonstrated the
immediate recruitment of Rab5 to the site of phagocytosis, followed by its replacement
by Rab7, visualized with this model system (Figure 4). This optimized assay can now be
used to quantify the recruitment of MHC II to phagosomes by expressing the inducible
MHC II trafficking reporter, described above, in this model system.
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Figure 4. Time-lapse of Rab5 and Rab7 recruitment to phagosomes.
RAW 264.7 macrophages were co-transfected with Rab5-GFP (green) and Rab7mCheery (red), and live cell fluorescence microscopy was performed to track the
localization of Rab5 and Rab7 to phagosomes formed after the engulfment of IgG-coated
PS/DVB beads. Images were captured with a 100× objective at 4-minute intervals
obtained from 2 independent experiment. Rab5 can be observed on the phagosome early
following phagosome formation (4 min), followed by replacement by Rab7 shortly
thereafter (>8 min). Data is presented where 0 min is the timepoint when the bead is first
fully engulfed by the macrophage. Arrows demark formation of the phagosome. Data are
representative of three independent experiments (n = 3). Scale bar is 10 µm.
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3.3 ERC1 May Facilitate Early Phagosome Maturation
Unpublished work from our lab previously showed that knocking down ERC1 abrogated
the delivery of MHC II to phagosomes, suggesting that ERC1 is required for mediating
this trafficking pathway. In other cells, ERC1 acts as a docking site for Golgi-derived
vesicles on lysosome-derived organelles. Should ERC1 serve a similar purpose in
pAPCs, it should be observed being deposited on phagosomal membranes, thereby
allowing for the recruitment of MHC II-bearing vesicles originated in the Golgi. To probe
this possibility, RAW 264.7 macrophages expressing MHC II-HaloTag were treated with
doxycycline and fluorescent HaloTag ligands to induce expression of and label MHC II
molecules, respectively. Phagocytosis assays using fluorescent IgG-coated beads were
performed, and the cells were fixed at various time points, followed by immunostaining
of ERC1 to track the recruitment of ERC1 and newly synthesized MHC II molecules on
phagosomes. ERC1 was immediately recruited to phagosomes (30 min to 1 h), followed
shortly by the recruitment of MHC II towards ERC1+ phagosomes (2 h to 4 h). At later
timepoints (6 h), ERC1 gradually dissipated while MHC II persisted on phagosomal
membranes (Figure 5). These results suggest that ERC1 may be involved in early MIIC
maturation through the initial recruitment of MHC II to phagosomes.
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Figure 5. Recruitment of ERC1 and MHC II to phagosomes.
Mouse macrophage cell line RAW 264.7 cells expressing MHC II-CD74-HaloTag were
treated with doxycycline for 1 h, followed by HaloTag labeling and addition of IgGcoated phagocytic targets (green). Phagocytosis assays were performed at various time
points and ERC1 was stained (yellow). Z-stacks were captured using
immunofluorescence microscopy and deconvolved in Leica Application Suite X using an
iterative blinded deconvolution algorithm. Data are presented as maximum intensity,
where 0 min represents the timepoint IgG-coated beads were initially added to
macrophage-containing wells. Data is representative of one independent experiment
(n = 1). Scale bar is 10 μm.
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3.4 Optimizing RT-qPCR Experiments for Detecting Gene
Expression
In addition to intracellular trafficking, MHC II can also be regulated at the level of
expression. As such, I needed to develop a method to detect MHC II expression in human
primary cells and cell lines. To ensure that we were specifically measuring mRNA levels
of our genes of interest, RT-qPCR primer efficiency tests were performed. Briefly, total
RNA was extracted from 1 x 106 THP-1 cells followed by synthesizing 50 ng cDNA. RTqPCR was then performed using serial dilutions of cDNA for each primer set to
determine whether primers fall within 90-110% efficiency and were suitable for usage in
future experiments when I test the effects of SARS-CoV-2 NSP5 on expression of genes
in primary human DCs (Table 2). In addition, melt curve analyses were performed for
primer pairs of each gene of interest to ensure a single, specific RT-qPCR product was
produced. Representative melt curves for each gene are shown in Figure 6.
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Table 2. RT-qPCR primer sequences used in this study.
Gene

Melting
Temperature
(°C)

Sequence

Primer
Efficiency
(%)

RT-qPCR primers

CIITA

F: 5′CTGAAGGATGTGGAAGACCTGGGAAAG-3′
R: 5′ACCCTCGTCCCCGATCTTGTTCTCACTC-3′

62.5
100.7
64.5

MHC II

F: 5'-CGAGTTCTATCTGAATCCTG-3'
R: 5’-GTTCTGCTGCATTGCTTTTGC-3

55.7
56.1

100.9

RFX5

F: 5′-TCCTTCAGTTCCATCGTTGAG-3’
R: 5′-TTCAGCTGTCCTCTTGACACC-3’

54.5
56.9

103.0

F: 5'-TCAAGGCTGAGAACGGGAAG-3'

57.0

R: 5'-CGCCCCACTTGATTTTGGAG-3'

56.7

GAPDH

97.3
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Figure 6. Representative RT-qPCR primer melt curve plots.
RNA was extracted from 1 x 106 THP-1 monocytes, followed by cDNA synthesis. A-D)
Serial dilutions of cDNA were used to perform RT-qPCR experiments for 40
amplification cycles to measure the efficiency of primers to detect CIITA (A), MHC II
(B), RFX5 (C), and GAPDH (D) mRNA. Melt curve analyses were performed to evaluate
the ability of primer pairs to produce single, specific RT-qPCR products for each gene.
Data are representative of one independent experiment (n = 1).
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3.5 Validation of Dual Luciferase Assay
To measure the activity of the MHC II and CIITA promoters, dual luciferase vectors
were generated containing ~200 bases upstream of the MHC II promoter, CIITA pI, or
CIITA pIV cloned into a pGL4 firefly luciferase vector, such that FLuc expression was
under control of the cloned promoter. This vector was co-transfected with a pRL-TK
regulatory vector that constitutively expresses RLuc, thereby acting as a transfection
control. These vectors were validated by seeding 3 x 105 HeLa cells onto 12-well tissue
culture plates, followed by a 3-day transfection using pGL4 reporter constructs for CIITA
pI and MHC II, as well as a promoter-less pGL4 construct to measure any leakiness in
the constructs. pRL-TK constructs were also co-expressed in these cells to account for
differences in transfection efficiencies between samples. We initially examined whether
any differences in CIITA pI and MHC II promoter activity would be observed in
response to NSP5 expression. No significant differences in MHC II and CIITA promoter
activities were observed between mock-transfected versus NSP5-expressing HeLa cells,
as was expected as these cells do not express the transcription factors required for either
CIITA (Figure 7A) or MHC II (Figure 7B) transcription. Through these experiments, I
optimized the DNA amount, lysate amount, reagent volume, and incubation times for
efficient measurements of FLuc and RLuc luminescence in future experiments using
more relevant cell lines.
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A)

B)

Figure 7. Dual luciferase analyses of alterations in CIITA pI and MHC II promoter
activity by NSP5.
HeLa cells were co-transfected with NSP5-FLAG and dual luciferase reporter constructs
for CIITA pI (pGL4-CIITA pI) or MHC II (pGL4-MHC II), followed by cell harvesting
at 72 h post-transfection using passive lysis buffer. Equal volume of protein was used to
measure firefly luciferase (FLuc) and renilla luciferase (RLuc) luminescence readings.
A-B) Promoter activity was calculated by dividing FLuc by RLuc to obtain relative
measurements of CIITA pI (A) and MHC II (B) promoter activity in NSP5-expressing
versus mock-transfected cells. Data represent mean ± SEM obtained from three
independent experiments (n = 3). Mann-Whitney test, n.s., not significant. UT =
untransfected. pGL4 = promoter-less vector control.
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Ultimately, these developed tools provide the ability to track MHC II expression and, for
the first time, the ability to directly monitor MHC II trafficking in live pAPCs. The MHC
II trafficking tools will be co-expressed along with fluorescent markers of the exocytic
(Rab3a, Rab8, and Rab27), endocytic (Rab5 and Rab7), recycling (Rab11 and Arf6), and
Golgi (Rab6) trafficking pathways, with live-cell imaging of the phagocytosis model
allowing for visualization of MHC II as it is transported from the ER/Golgi to
phagosomes. Unfortunately, due to the COVID-19 pandemic, I was unable to pursue
these experiments further, but I was able to leverage some of these tools to understand
how SARS-CoV-2 manipulates antigen presentation on MHC II.
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Chapter 4

4

Results – Assessing the Effects of SARS-CoV-2 NSP5
on MHC II Expression

4.1 Introduction
Previous studies have demonstrated that severe infections with SARS-CoV-2
downregulated MHC II expression in pAPCs, and in vitro infections in macrophages
reduced levels of MHC II surface expression100,101. The mechanisms for this suppression
remain unknown; however, it may involve epigenetic reprogramming of MHC II
expression or manipulation of MHC II trafficking—common mechanisms utilized by
pathogens to inhibit antigen presentation and adaptive immune responses. Recent
interactome analyses have identified SARS-CoV-2 NSP5 to interact with host HDAC2—
an epigenetic regulator of MHC II expression. To gain an idea of how NSP5 may impair
host cell responses, our lab generated untagged and FLAG-tagged expression vectors for
NSP5.

4.2 Subcellular Localization of NSP5 Provides Clues to
Host Function Impairments
I first determined the subcellular localization of NSP5 relative to various organelles using
immunofluorescence microscopy of HeLa cells co-transfected with NSP5-FLAG, the
Golgi marker GalT-mCherry, the ER marker KDEL-GFP, and stained with anti-FLAG
and Hoechst to demark the nucleus. I demonstrated that NSP5 was present in the cytosol,
localizing strongly to the nucleus, weakly to the ER, and showing no localization to the
Golgi (Figure 8A). This strong nuclear localization suggests that NSP5 may possess a
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potential function in altering molecular pathways and host responses within the
nucleus120,121.
To confirm whether NSP5 is indeed localized to the nucleus, HeLa cells expressing
FLAG-tagged NSP5 were treated with the nuclear import inhibitor ivermectin.
Significant reductions in the fraction of nuclear NSP5 was observed when compared to
DMSO-treated cells (Figures 8B-C). These results suggested that NSP5 utilizes an
importin-mediated trafficking pathway or hijacks a host protein to enter nuclei.
Unpublished data from a colleague in the lab showed that NSP5 colocalized with
HDAC2 in the nucleus, consistent with previous reports identifying interactions between
HDAC2 and NSP5. HDAC2 is a nuclear protein known to function as a regulator of
expression of multiple genes through deacetylating histones. The presence of NSP5 on
the nucleus suggests that it may interact with HDAC2 to dysregulate target gene
expression. Specifically, it is speculated that NSP5 downregulates MHC II and its
upstream transcriptional regulators through an HDAC2-mediated mechanism.
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Figure 8. NSP5 is localized to host nuclei.
A) Visualization of NSP5 subcellular localization. HeLa cells were co-transfected with
NSP5-FLAG (yellow), GalT (magenta), and KDEL (cyan), followed by staining with
anti-FLAG and Hoechst (grey). Immunofluorescence imaging was performed to observe
the localization of NSP5 relative to fluorescent markers of subcellular organelles. B)
Representative immunofluorescence microscopy images of NSP5 localization in DMSOversus ivermectin-treated cells. HeLa cells expressing NSP5-FLAG were treated with 25
µM of ivermectin or DMSO for 90 min, followed by staining with anti-FLAG and
immunofluorescence microscopy to observe nuclear localization of NSP5.
C)
Quantification of NSP5 nuclear fraction between DMSO- and ivermectin-treated cells.
Data are presented as mean ± SEM and are representative of three independent
experiments (n = 3). Mann-Whitney test, **, p < 0.01. Scale bar is 10 µm.
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4.3 NSP5 Downregulates CIITA and MHC II
To investigate whether NSP5 has the capacity to suppress MHC II expression, RAW
264.7 murine macrophages were transduced with empty or NSP5-expressing pLVXzsGreen lentiviral vectors. Following transduction, plasma membranes were stained using
wheat germ agglutinin (WGA), and immunofluorescence microscopy compared
differences in MHC II expression in these two samples (Figures 9A-B). Analysis of
transduced zsGreen+ cells demonstrated that expression of MHC II was significantly
reduced in NSP5-expressing cells (Figure 9C). To probe the possibility that this
reduction in MHC II expression is due to NSP5-mediated alterations in MHC II
trafficking, the proportion of surface MHC II versus cytosolic MHC II was measured
based on colocalization with WGA. We observed no significant differences between
surface MHC II levels in both samples (Figure 9D), suggesting that NSP5 downregulates
MHC II independent of mis-trafficking molecules away from the cell surface.
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Figure 9. NSP5 reduces MHC II expression independent of altering membrane
trafficking.
RAW 264.7 macrophages were transduced with empty (Mock) or NSP5-expressing
(NSP5) lentiviral vectors for 72 h and stained with anti-MHC II and the plasma
membrane marker wheat germ agglutinin (WGA). A-B) Immunofluorescence
microscopy was performed to detect MHC II expression and localization in mock
infected (A) versus NSP5-expressing (B) macrophages. C) Quantification of mean
fluorescence intensity (MFI) of MHC II in mock infected versus NSP5-expressing cells.
Data is normalized to mock samples. D) Quantification of the fraction of surface MHC II
between mock infected versus NSP5-expressing cells. WGA was used to demark plasma
membranes and determine the proportion of MHC II on the cell surface relative to the
cytosol. Images were captured on an epifluorescence microscope at 100 × magnification
and deconvolved in Leica Application Suite X using an iterative blinded deconvolution
algorithm. Data are presented as mean ± SEM and are representative of three independent
experiments (n = 3). Mann-Whitney test, **, p < 0.01; n.s., not significant. Scale bar is 10
µm. Data courtesy of Brandon Dickson.
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In addition to mis-trafficking MHC II molecules, some pathogens limit antigen
presentation by suppressing MHC II expression. I sought to measure the mRNA levels of
MHC II, CIITA, and RFX5 in NSP5-expressing primary human DCs, as expression of
these genes were observed to be downregulated in patients with COVID-19. Briefly,
primary DCs were transduced with empty or NSP5-expressing pLVX-zsGreen lentiviral
vectors, followed by IFNγ stimulation to induce CIITA and MHC II expression. Cells
were then sorted based on expression of zsGreen via fluorescence activated cell sorting
(FACS) to ensure measurements of gene expression were conducted in transduced cells
only. Following RNA isolation and cDNA synthesis, CIITA and MHC II mRNA levels
were measured using RT-qPCR, with expression of these genes significantly reduced in
NSP5-expressing cells (Figure 10), suggesting that NSP5 expression is sufficient to
suppress CIITA and MHC II expression. This reduction was not observed in RFX5, with
no significance differences in mRNA levels between NSP5- and empty vector-transduced
cells, suggesting that the antagonistic effect of NSP5 on CIITA and MHC II transcription
is not caused via global suppression of gene expression but, instead, involves selective
targeting of the CIITA and MHC II genes.
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Figure 10. RT-qPCR quantification of RFX5, CIITA, and MHC II expression.
Human primary dendritic cells were infected with empty zsGreen (Mock) or NSP5zsGreen (NSP5) lentiviral vectors for 72 h and treated with IFNγ for 24 h. zsGreen+ cells
were sorted via FACS followed by RNA extraction and cDNA synthesis. RFX5 (orange),
CIITA (blue), and MHC II (pink) mRNA levels were quantified by RT-qPCR reactions
performed for 40 amplification cycles using a constant amount of cDNA (50 ng). Data
are presented on a box-and-whisker plot, with the median, maximum, minimum, and
quartiles shown. Data are relative to GAPDH mRNA expression and normalized to mock
(empty vector-transduced) samples. Data are obtained from four independent experiments
(n = 4). Mann-Whitney test, *, p < 0.05; n.s., not significant.
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4.4 NSP5 Inhibits MHC II and CIITA Promoter Activity
While RT-qPCR analysis confirmed downregulation of MHC II and CIITA by NSP5, the
mechanisms by which NSP5 suppresses these genes remain unknown. To address this
question, I investigated whether NSP5 inhibits the activity of MHC II and CIITA
promoters. RAW 264.7 macrophages were co-transfected with NSP5, a FLuc construct
controlled by an MHC II or CIITA promoter, and a regulatory pRL-TK vector expressing
constitutive RLuc. Macrophages were then lysed and harvested, and a dual luciferase
assay was performed to measure the effects of NSP5 on MHC II and CIITA promoter
activities. Measurements of FLuc and RLuc luminescence levels demonstrated that both
CIITA pI (Figure 11A) and MHC II (Figure 11B) promoter activities were significantly
inhibited in NSP5-expressing macrophages compared to macrophages transfected with an
empty lentiviral vector. In contrast, CIITA pIV—the promoter expressed by nonhematopoietic cells—was minimally active in these cells, and NSP5 had no measurable
impact on activity of this promoter (Figure 11C). These data indicate that the altered
MHC II expression mediated by NSP5 occurs through inhibition at the level of CIITA
promoter I activity specifically.
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Figure 11. NSP5 inhibits CIITA pI and MHC II promoter activity but not CIITA
pIV activity.
A-C) Promoter activity was quantified in RAW 264.7 macrophages co-transfected with
NSP5-FLAG and dual luciferase reporter constructs of the CIITA pI (A), MHC II (B), or
CIITA pIV (C) promoters. Promoter activity is relative to RLuc. Data are representative
of mean ± SEM obtained from three independent experiments (n = 3), with duplicate
samples analyzed in each experiment. Mann-Whitney test, *, p < 0.05; n.s., not
significant. UT = untransfected. pGL4 = promoter-less vector control.
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4.5 HDAC2 Knockdown Restores CIITA and MHC II
Expression
While I demonstrated that expression of NSP5 is sufficient to downregulate MHC II and
CIITA expression at the levels of both mRNA and promoter activity, it remains unknown
how NSP5 manipulates this pathway. Previous studies identified interactions between
SARS-CoV-2 NSP5 and human HDAC2, which is known to repress CIITA and MHC II
expression via deacetylation of the histone tails. To elucidate the role of NSP5 in this
pathway, HDAC2 was knocked down in NSP5-expressing DCs using siRNA to assess
the resulting effects on MHC II and CIITA expression. Western blot was performed to
confirm knockdown of HDAC2 (Figure 12A). RT-qPCR analysis demonstrated that
when compared to cells treated with non-targeting siRNA, HDAC2 knockdown restored
expression of CIITA (Figure 12B) and MHC II (Figure 12C) in human DCs despite the
presence of NSP5. To further investigate the effects of NSP5 on MHC II and CIITA
transcription, a dual luciferase assay was performed to measure differences in promoter
activity of these genes in NSP5+/HDAC2- RAW 264.7 macrophages. While knocking
down HDAC2 rescued CIITA pI activity by almost 2-fold (Figure 12D), this effect was
not observed on the MHC II promoter regardless of whether HDAC2 is present or absent
(Figure 12E). It is unclear why there is a disparity between MHC II promoter activity
and mRNA levels in the presence of NSP5, but this discordance may be due to the
absence of distal regulatory sites in the MHC II promoter that are known to be required
for de-silencing of the MHC II loci13. Altogether, these results suggest that
downregulation of MHC II and CIITA can be reverted by preventing NSP5 from
targeting HDAC2.
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Figure 12. HDAC2 knockdown reverts the effects of NSP5 on CIITA and MHC II
expression.
A) Detection of HDAC2 knockdown. Human primary DCs were treated with HDAC2targeting siRNA (siHDAC2) or non-targeting siRNA (siNT) for 96 h. Western blot
analysis was performed to confirm HDAC2 knockdown in siHDAC2-treated cells.
GAPDH was used as a housekeeping gene to confirm equal loading. B-C) RT-qPCR
quantification of CIITA (B) and MHC II (C) expression in HDAC2 knockdown human
primary DCs. Cells were infected with lentiviral vectors expressing NSP5-zsGreen for 72
h, followed by treatment with IFNγ and siRNA for 24 h and 96 h, respectively. mRNA
levels were quantified by RT-qPCR reactions performed for 40 amplification cycles
using a constant amount of cDNA (50 ng) and are relative to GAPDH mRNA expression.
Data are presented on a box-and-whisker plot outlining the median, maximum, minimum,
and quartiles. D-E) Dual luciferase analysis of CIITA pI (D) and MHC II (E) promoter
activity in HDAC2-deficient macrophages. Promoter activity was quantified in HDAC2knockdown RAW 264.7 macrophages co-transfected with NSP5-FLAG and dual
luciferase reporter constructs of the CIITA pI or MHC II promoters. Promoter activity is
relative to RLuc and normalized to siNT. Data are representative of mean ± SEM
obtained from a minimum of three independent experiments. Mann-Whitney test, **, p <
0.01; ***, p < 0.001; n.s., not significant.
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4.6 Inactivating NSP5 Proteolytic Activity Has No Effect on
CIITA and MHC II Expression
NSP5 is comprised of three domains: a catalytic domain comprised of two globular
domains (A and B) which form a catalytic dimer at the core of which are the catalytic
residues H41 and C145, and a C-terminal domain (B’) which functions to stabilize
interactions between the catalytic site and target peptides. We generated deletion mutants
of the catalytic A/B and B’ domains, as well as point mutations of these two critical
residues (H41A and C145S) to probe whether the catalytic function of NSP5 is
responsible for altering HDAC2 activity and suppressing MHC II and CIITA expression
(Figure 13A). While the point mutants expressed well, minimal expression of the
deletion mutants was observed, precluding further analysis of these mutants.
RAW 264.7 macrophages expressing dual luciferase reporter constructs for MHC II and
CIITA pI were transfected with either wildtype (WT) NSP5 or with the NSP5 point
mutants, and then promoter activity was measured. Unexpectedly, inactivation of the
catalytic sites had no observable effect on the expression of CIITA (Figure 13B) and
MHC II (Figure 13C).
Previous computational studies predicted that NSP5 may proteolytically cleave HDAC2
near its nuclear localization signal, thereby preventing its nuclear translocation and
function. We showed via immunofluorescence microscopy analysis that the catalytically
inactive NSP5 mutants failed to alter the localization of HDAC2 when compared to WT
NSP5 (Figure 13D). These results suggest that NSP5 suppresses CIITA and MHC II
expression independent of its proteolytic function or manipulation of HDAC2
localization.
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Figure 13. Analysis of NSP5 point mutations on CIITA pI and MHC II promoter
activity.
A) Overview of NSP5 mutations. Wildtype (WT), deletion mutations of the N- (Δ1-192)
and C-terminal (Δ199-306), and point mutations (H41A, C145S) on the catalytic site of
NSP5 were generated to assess their effects on CIITA and MHC II expression. B-C) Dual
luciferase analysis of CIITA pI (B) and MHC II (C) promoter activity in RAW 264.7
macrophages transfected with NSP5WT, NSP5H41A, or NSP5C145S. Promoter activity is
relative to RLuc and normalized to WT. D) Immunofluorescence microscopy analysis of
NSP5 mutants’ subcellular localization. Z-stacks were captured on an epifluorescence
microscopy at 100× magnification and deconvolved in Leica Application Suite X using
an iterative blinded deconvolution algorithm. Data are representative of three
independent experiments (n = 3). Kruskal-Wallis test, n.s., not significant. Scale bar is 10
µm. Panel D is courtesy of Peter Guo.
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4.7 HDAC2 Expression is Unaltered by NSP5
While it has not been established that HDAC2 can be activated via cleavage, other
HDACs have been shown to be cleaved at the C-terminus, leading to their activation and
localization to the nucleus where they can silence expression of target genes122,123. As
NSP5 primarily functions as a cysteine protease via cleavage of the SARS-CoV-2
polyprotein shortly after viral entry and translation in the host cytosol, NSP5 was
speculated to alter HDAC2 activity via cleavage. While previous results showed that
inactivating the proteolytic function of NSP5 did not restore MHC II and CIITA
expression, western blot analyses were performed to probe the possibility that HDAC2 is
proteolytically processed in the presence of NSP5. Should NSP5 cleave HDAC2 at the
predicted location, HDAC2 would undergo a ~10 kDa decrease in its apparent mass or,
alternatively, may be targeted for proteasomal degradation and, thus, decreasing its
abundance. I did not observe the appearance of a lower-mass band indicative of HDAC2
cleavage nor were there any differences in HDAC2 expression between mock-transfected
and NSP5-expressing cells (Figure 14). Therefore, these results confirmed that the effect
of NSP5 on the MHC II transcriptional machinery is independent of HDAC2 cleavage
but may involve other post-translational modifications or altered protein targeting that
modulate HDAC2 enzymatic activity at the CIITA and MHC II promoters.
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Figure 14. Western blot analysis of HDAC2 cleavage.
HeLa cells were transfected with empty (Mock) or NSP5-expressing (NSP5) lentiviral
vectors, or were left untransfected (UT), for 72 h followed by lysis. Protein lysates were
added to 10 % acrylamide gel at an equal volume. Western blot analysis compared
differences in HDAC2 expression between samples. GAPDH was used as a housekeeping
gene to normalize protein loading.
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4.8 NSP5-Mediated Modulation of HDAC2 May Be Shared
Between SARS-CoV-2 and Other Related Bat
Coronaviruses
While our findings suggest that SARS-CoV-2 has the capacity to impair immune
responses in humans through NSP5-mediated downregulation of MHC II expression, it
remains poorly understood why a virus that likely originated in bats would have this
specific effect on HDAC2 in human pAPCs. There are two possible explanations for this
phenomenon: either HDAC2 is sufficiently conserved between humans and bats to
preserve the NSP5 activity between species, or alternatively, NSP5 itself is highly
conserved across coronaviridae, thereby mediating similar phenomena across host
species. To address these possibilities, a phylogenetic tree was generated using protein
sequences of NSP5 expressed by coronaviruses representative of the four major
coronaviridae clades, including members known to infect bats and humans. NSP5 protein
sequences are identical not only between SARS-CoV-2 and the original SARS-CoV but
also with the bat coronavirus isolate, BANAL-20-236, which was recently identified as a
potential link to the progenitor bat coronavirus prior to zoonotic transmission in humans
(Figure 15A)74. Otherwise, NSP5 was highly diverse across the coronaviridae family.
Likewise, a second phylogenetic tree was generated using protein sequences of HDAC2
from multiple species. HDAC2 was found to be extremely conserved across vertebrates,
with less than 1 % protein sequence differences observed between species, including
across multiple bat species (Figure 15B). Ultimately, although SARS-CoV-2 likely
originated in bats, the high conservation of HDAC2 between bats and humans suggests
that SARS-CoV-2 and its bat progenitor virus may utilize a similar mechanism involving
NSP5 to impair adaptive immune responses. Unfortunately, bats are inherently tolerant to
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viral infections compared to humans, allowing for them to act as viral reservoirs and
transmit viruses without straining their immune systems124.
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B)

Figure 15. Phylogenetic analyses of ancestral NSP5 and HDAC2.
A-B) Phylogenetic trees of amino acid sequences of NSP5 (A) from representative
species of the four genera of coronaviruses and HDAC2 (B) across a range of vertebrate
species. Scale indicates the degree of evolutionary divergence, and numbers on branch
points indicate bootstrap values.
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Chapter 5

5

Discussion

5.1 Hypotheses and Answers
In this thesis, I tested the hypothesis that phagosome-derived TLR signaling activates
ERC1 to facilitate the delivery of newly synthesized MHC II molecules via a direct
Golgi-to-MIIC trafficking pathway. While it remains unclear which trafficking pathway
is responsible for delivering MHC II to phagosomes, immunofluorescence microscopy
and phagocytosis assays utilizing the inducible MHC II-HaloTag reporter demonstrated
that ERC1 is likely involved in this process based on the recruitment of MHC II to
ERC1-bearing phagosomes shortly after phagocytosis.
I also tested the hypothesis that SARS-CoV-2 NSP5 suppresses MHC II expression via
interactions with HDAC2. Critically, I determined that NSP5 is capable of suppressing
MHC II expression, and this suppression is mediated by HDAC2-dependent inhibition of
CIITA and MHC II transcription. RT-qPCR and dual luciferase analyses of human
primary DCs and cell-line macrophages showed that the presence of NSP5 reduced MHC
II and CIITA expression at the level of mRNA and promoter activity. Additionally, RNA
silencing of HDAC2 reverted expression of MHC II and CIITA despite the presence of
NSP5, suggesting that HDAC2 is a necessary component for SARS-CoV-2-mediated
antagonism of this pathway. While HDAC2 is not directly involved in the IFNγ signaling
pathway, it is a major regulator of several components of the MHC II antigen
presentation pathway, specifically by repressing CIITA and MHC II expression. Our
findings implicate NSP5 as a biological activator of HDAC2 to downregulate CIITA and
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MHC II, leading to impaired adaptive immune responses in infected individuals.
Critically, I identified HDAC2 as a potential target for preventing SARS-CoV-2
infections from overwhelming patients’ immune system, as its inhibition may outright
block viral access to the MHC II transcriptional machinery, thereby restoring host
immune responses.

5.2 Rationale of Thesis
The investigation into MHC II trafficking pathways was based on several key findings.
Firstly, our lab previously discovered the presence of ERC1 and Rab6 on phagosomal
membranes of macrophages. Based on the literature, these proteins are major regulators
of Golgi export pathways and have been shown to facilitate the delivery of Golgi-derived
vesicles to target organelles in other cell types51,125. Lastly, unpublished data from our lab
demonstrated that knocking down ERC1 with shRNA abrogates the delivery of MHC II
to MIICs. Based on these findings, we postulated that ERC1 is involved in delivering
MHC II directly to MIICs through an uncharacterized trafficking pathway. Should we
observe this phenomenon, it would resolve the 2-decade-old controversy surrounding the
pathways responsible for intracellular MHC II trafficking. Investigating the components
required for delivering MHC II to its designated location, either the phagosome or cell
surface, is important not only from a mechanistic perspective but is also crucial for
understanding how pathogens can evade host immunosurveillance. Many pathogens can
prevent the generation of adaptive immune responses by redirecting MHC II molecules
away from the cell surface. By identifying the regulators involved in transporting MHC II
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for antigen presentation, we can target these components and prevent pathogens from
hijacking molecular pathways and ensure that immune responses are mounted.
SARS-CoV-2 is one such pathogen capable of dysregulating CD4+ T cell-mediated
responses despite these adaptive immune cells’ role in controlling infections. While
macrophages and DCs are capable of being infected by SARS-CoV-2, these infections
are generally non-productive and do not drive production of pro-inflammatory
cytokines126. However, the resultant effects of these infections on these innate immune
cells may still have profound immunological impacts in patients. Normally, macrophages
and DCs play a major role in presenting pathogen-derived peptides on MHC II to CD4+ T
cells, leading to CD4+ T cell activation that initiates effector functions to reduce viral
spread. For example, activated CD4+ T cells can differentiate into T follicular helper
(Tfh) cells that play a protective role by activating B cells to produce neutralizing
antibodies against foreign SARS-CoV-2 antigens125,126. However, Tfh cell differentiation
and germinal centers have been observed to be diminished in patients with severe
COVID-19, attributing to short-lived and reduced humoral responses. Likewise, the Th1
responses crucial for mediating cell-mediated responses are depleted while Th2 responses
are overreactive in COVID-19 patients, potentially leading to non-productive T cell
activation and exhaustion127,128. Consequently, these non-functional T cell responses
enable the virus to propagate in our airways and continually infect cells. SARS-CoV-2
proteins, such as ORF6 and ORF8, can then further inhibit antiviral responses and
mediate non-productive secretion of proinflammatory cytokines77,78. This combination of
reduced viral clearance by effector T cells and antibodies along with excessive
production of pro-inflammatory cytokines can exacerbate inflammatory responses,
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ultimately leading to the hallmark cytokine storm and multiorgan failure associated with
COVID-19129.
How SARS-CoV-2 facilitates these host defense defects remains unknown, but we
speculate that downregulation of MHC II in infected pAPCs is an underlying factor.
Many studies demonstrated that infections with SARS-CoV-2 reduced MHC II levels in
COVID-19 patients’ pAPCs, suggesting that virulence factors expressed by SARS-CoV-2
may be responsible for mediating this immunoevasion78,102,130. Blocking MHC II access
to the surface is a common strategy utilized by pathogens to escape host immune
responses. While multiple pathogens utilize different virulence factors to target and
inhibit the MHC II antigen presentation pathway, these mechanisms all revolve around
either one of two strategies. The first strategy is the redirection of MHC II trafficking
away from the cell surface. For example, HSV type 1 glycoprotein B hijacks the MHC II
trafficking pathway by binding to and confining MHC II molecules to subcellular
vesicles, thereby preventing their association with exogenous peptides131,132. Likewise,
infections with Salmonella Typhimurium abrogates antigen presentation of DCs by
inducing polyubiquitination of MHC II, thereby promoting the internalization and
degradation of surface MHC II molecules through endosomal proteases133,134. The second
strategy pathogens use to block antigen presentation is the antagonism of MHC II
transcription. For example, infections with Leishmania donovani selectively inhibits
transcription of MHC II genes through a cyclic AMP-dependent manner135. Moreover,
Epstein-Barr virus transactivator protein Zta represses CIITA pIII activity in infected B
cells, resulting in reduced MHC II expression136.
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Our investigation into how SARS-CoV-2 suppresses antigen presentation is based on a
key finding from the literature identifying NSP5 to interact with HDAC2, implicating a
potential mechanism by which SARS-CoV-2 blocks MHC II expression. We proposed
that SARS-CoV-2 utilizes NSP5 to antagonize the MHC II transcriptional machinery. I
demonstrated that the presence of NSP5 decreased levels of MHC II transcription and
that

HDAC2

knockdown

reverted

this

suppressed

phenotype.

Furthermore,

immunofluorescence microscopy showed no reductions in the proportion of surface MHC
II levels in NSP5-expressing cells compared to mock-infected cells, precluding the
possibility that the decreased levels of MHC II is via NSP5-mediated manipulation of
vesicular trafficking pathways to prevent MHC II from reaching the cell surface.

5.3 TLR and FcγR Signaling Activates ERC1 to Regulate
MHC II Trafficking
While the controversy surrounding MHC II trafficking to phagosomes has existed for
over two decades, our findings suggest that ERC1 is a major regulator of this process.
Previous data showed that ERC1 is recruited to phagosomes during early stages of
maturation preceding the recruitment of MHC II, and ERC1 silencing abrogates the
formation of MIICs in macrophages. In this thesis, I demonstrated that newly synthesized
MHC II is recruited directly to ERC1-bearing phagosomes, further supporting the role of
ERC1 in mediating this trafficking pathway.
Previous studies into MHC II trafficking were limited, in the sense that they lacked the
molecular tools required to visualize the intracellular movement of MHC II. In fact, most
prior studies relied on either immunofluorescence microscopy of fixed cells, or on broad-
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spectrum

inhibitors

of

the

trafficking

pathways,

thereby

incurring

several

limitations137,138. Interpretation of fixed-cell images can be highly biased based on the
timepoints where cells are fixed and analyzed. For example, some of the studies taking
this approach looked at long timepoints following induction of MHC II signaling (6 hours
or longer)—long enough for mature MHC II to both reach the cell surface and be reinternalized as part of normal membrane protein recycling137,139. A more recent study has
shown that a significant portion of endocytosed MHC II molecules are targeted for
degradation rather than transported to the MIIC140. Likewise, inhibitor-based studies can
be difficult to interpret. For example, endocytosis inhibitors will not only impair the
endocytosis of MHC II but also of small antigens, with some even interfering with
phagocytosis32,37,141–143. Thus, in these studies, alterations in the formation of the MIIC
may result from a failure to engulf antigens rather than from selective blocking of the
endocytic route of MHC II delivery. By developing a live-cell-compatible MHC II
trafficking reporter, we will be able to visualize the trafficking process as it occurs.
Moreover, as this system is inducible, MHC II expression can be decoupled from other
stimuli and from the use of inhibitors, therefore avoiding some of the issues faced by
prior studies.
While it was initially predicted that TLR signaling would activate ERC1 to facilitate the
delivery of MHC II to phagosomes, our data showed that ERC1 is recruited to
phagosomes through FcγR-mediated phagocytosis of IgG-coated beads, suggesting that
the potential effect of ERC1 on MHC II trafficking is independent of the canonical TLRmediated NFκB activation pathway. However, while it has not been established whether
FcγR-mediated phagocytosis can induce NFκB activation, a previous study has shown
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that treatment with IgG-coated beads reduced levels of IκBα and reduced cytosolic
sequestration of NFκB in bone marrow-derived macrophages144. Indeed, FcγR signaling
can activate mitogen-activated protein kinases, which in turn can activate NFκB via Syk
kinase145. Likewise, stimulation of FcγR in THP-1 macrophages using human IgG was
observed to be sufficient to degrade IκBα and activate NFκB146. Our data are consistent
with these findings, as we demonstrated that ERC1 is recruited to phagosomes when
using either IgG-coated beads or fluorescently labeled bacteria. Ultimately, these results
suggest that both FcγR-mediated and TLR-mediated signaling are capable of activating
ERC1, allowing for ERC1 to modulate the trafficking of newly synthesized MHC II
molecules to MIICs.
In addition to regulating the delivery of MHC II to the MIIC, ERC1 may also be involved
in regulating MHC II expression. While IFNγ is required for inducing expression of
MHC II, NFκB activation is required for maximal MHC II expression downstream of
TLR4 and TLR9, with NFκB potentially driving CIITA-independent transcription of
MHC II genes in macrophages69,147. Given the central role of ERC1 in regulating NFκB
activation via assembly of the IKK complex, it is quite possible that knockdown of ERC1
will not only impair MHC II delivery to the MIIC but may also reduce or eliminate MHC
II expression in response to phagocytosed pathogens. The RT-qPCR and dual luciferase
assays developed in this thesis will enable us to study this pathway in depth, while the
inducible MHC II-HaloTag reporter will allow us to study the effects of ERC1
knockdown on MHC II trafficking without imparting any effects on endogenous MHC II.
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5.4 NSP5-HDAC2-CIITA-MHC II Axis
In this thesis, I identified a novel function of SARS-CoV-2 NSP5 outside of its role in
viral replication, wherein it alters host immune responses by inhibiting MHC II and
CIITA transcription. How NSP5 antagonizes expression of these genes is still up to
debate, but we have shown that HDAC2 is likely involved in this process, as it is a
known epigenetic regulator of MHC II and CIITA. While it is well established that
HDACs regulate a vast repertoire of cellular activities through eukaryotic gene
regulation, it remains poorly understood how these proteins themselves are regulated. For
example, while HDAC3 and HDAC4 are known to be cleaved at the C-terminal, the
effect of this post-translational modification is unclear. One study observed that caspasedependent cleavage degrades HDAC4, while another study implicates HDAC4 activity is
increased upon cleavage by the same caspases123,148. Likewise, while both HDAC1 and
HDAC4 are known to undergo SUMOylation that potentiates their biological activity, it
is unclear how their stability and expression is modulated149–151. Finally, there are no
reports of HDAC2 cleavage being linked to increased activity.
In fact, NSP5 is predicted to have a cleavage site on HDAC2 that would prevent its
nuclear transport and ability to attenuate inflammatory responses105,110. Other
computational studies predict that blocking HDAC2 nuclear localization is cleavageindependent but initiates inflammatory responses by preventing HDAC2-mediated
cytosolic sequestration of NFκB—a major regulator of transcription of multiple
proinflammatory genes, including MHC II107. Intriguingly, our findings contrast with
both prediction models, as we showed that HDAC2 does not undergo proteolytic
processing in the presence of NSP5. Likewise, we observed no differences in HDAC2
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nuclear localization in cells expressing wildtype NSP5 or NSP5 point mutants in which
the catalytic sites are functionally inactivated. Currently, it remains unclear how the
cysteine protease NSP5 modulates HDAC2 activity independent of proteolytic
modifications. Previous studies have reported that coronaviruses, including MERS-CoV
and SARS-CoV, can alter histone modifications and activate or repress expression of
targeted genes, albeit the specific viral components have yet to be identified152. However,
phylogenetic analyses demonstrated that NSP5 sequences are identical in SARS-CoV and
SARS-CoV-2, and moderately conserved in MERS-CoV. Consistently, our findings
showed that SARS-CoV-2 NSP5 selectively downregulates MHC II and CIITA,
suggesting that NSP5 may be potentiating HDAC2-mediated histone modification
independent of its proteolytic activity.

5.5 Limitations and Pitfalls
One major pitfall of our vesicular trafficking experiments is that surface MHC II may
enter an alternative pathway, such as a receptor recycling pathway, and from there be
directed to the phagosome. As such, we may not be able to fully characterize the
trafficking pathway utilized by MHC II to reach the phagosome using our current
fluorescent markers to probe indirect endocytic or direct Golgi trafficking pathways.
Should we observe that MHC II is not transported via either of these pathways, further
studies will use fluorescent markers of recycling pathways, such as Rab11 or Arf6 to
probe this possibility. While unlikely, delivery of MHC II from other organelles can be
assessed through the expression of organelle-specific markers, such as LC3-GFP to
demark autophagosomes. A more likely pitfall is that multiple pathways may be involved
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in the delivery of MHC II to phagosomes. By performing pulse-chase experiments with
our inducible MHC II-HaloTag reporter, we can perform high-temporal resolution
imaging of MHC II trafficking that will allow us to determine which pathways deliver
MHC II molecules to phagosomes at different timepoints following induction of MHC II
expression.
An intriguing finding from our investigation into the effects of NSP5 on MHC II
expression was that knocking down HDAC2 failed to restore MHC II promoter activity,
suggesting that HDAC2 may not be involved in NSP5-mediated antagonism of the MHC
II transcriptional machinery. However, this seemingly inconsistent finding may be
attributed to the limitations of our dual luciferase MHC II reporter construct. While it is
well established that RFX5 and CIITA assemble on the MHC II enhanceosome by
binding to the promoter-proximal W-X1-X2-Y regulatory elements, novel regulatory
elements containing inverted W-X1-X2-Y motifs have been identified to be positioned
several kilobases from the transcriptional start site153. These promoter-distal regulatory
elements are also bound by RFX5 and CIITA, leading to histone acetylation in vivo13,
suggesting that MHC II transcription is regulated through a mechanism more complex
than originally thought, involving a combination of both promoter-proximal and
promoter-distal regulatory elements. Consistent with this model, we saw restoration of
MHC II mRNA levels from the endogenous promotor in NSP5-expressing cells treated
with an HDAC2-depleting siRNA, while an equivalent restoration of MHC II promotor
activity was not observed in our dual luciferase MHC II reporter construct which only
possesses the promoter-proximal W-X1-X2-Y regulatory elements but not the promoterdistal regions. In addition, because measurements of promoter activity were based on
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dual luciferase reporter vectors, there is a possibility of incomplete or altered histone
recruitment and, therefore, a difference in HDAC2 activity on these vectors, which may
account for the differences observed between genomic versus vector-based expression
levels of MHC II.

5.6 Future Work
While I was unable to investigate the roles of the endosomal trafficking regulators Rab5
and Rab7 in the indirect endolysosomal trafficking pathway, I have optimized the toolset
and framework that will allow us to study this mechanism. Particularly, time-lapse
microscopy and phagocytosis assays can be utilized in conjunction with our inducible
MHC II-HaloTag expression system to explore how different regulators are involved in
the trafficking of MHC II to phagosomes. To explore the roles of ERC1 in the canonical
NFκB activation pathway, RT-qPCR and dual luciferase assays can be utilized to
quantify the effects of ERC1 knockdown on NFκB and MHC II expression. Lastly, ERC1
has been identified as an interactor of SARS-CoV-2 NSP13. As we have observed that
ERC1 is involved in regulating the delivery of MHC II to MIICs, it would be interesting
to further investigate whether NSP13 may antagonize this trafficking pathway as an
immunoevasion strategy.
An important consideration of this thesis was to study how NSP5-mediated suppression
of MHC II can impact antigen presentation and CD4+ T cell activation. It would be
intriguing to explore whether NSP5 is responsible for the impaired cell-mediated and
humoral immune responses observed in patients with COVID-19. Further study could
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address this possibility through a T cell activation assay. Specifically, PBMCs can be
stimulated with a recombinant SARS-CoV-2 spike protein and stained with a CD4
surface antibody dye to obtain a pool of spike antigen-specific CD4+ T cells. We can then
co-culture these T cells with NSP5-expressing DCs and induce antigen presentation using
the same recombinant spike protein, wherein flow cytometry will assess differences in
CD4+ T cell proliferation and activation using cell proliferation dyes or antibodies of
surface T cell activation markers, including CD25 and CD71154,155. Should we observe
reduced proliferative capabilities or reduced expression of surface T cell activation
markers, it would provide strong indications that NSP5 is responsible for the diminished
immune responses in patients with COVID-19. In addition, while we observed no
evidence suggestive of HDAC2 cleavage in the presence of NSP5, it is plausible that
western blot analyses may not be sensitive enough to detect small cleavage sites. Other
HDACs have been shown to be proteolytically cleaved at the C-terminus, resulting in
their activation. One potential experiment to overcome this issue would be to generate an
HDAC2 reporter construct tagged with different monomeric fluorescent protein
biosensors (e.g. mVenus and mTurquoise2) on either ends of the gene, and then coexpressing NSP5 with this construct in primary human DCs. We could exploit these
fluorescent protein biosensors by performing a Förster resonance energy transfer (FRET)
analysis to determine whether HDAC2 is cleaved in the presence of NSP5 based on the
disappearance of the FRET signal on either biosensor156. Should we observe a loss of
FRET signal, it would confirm whether HDAC2 activity is modulated by NSP5-mediated
cleavage, and further approaches such as high-resolution mass spectrometry or Edman
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degradation of the immunoprecipitated fragments can be used to identify the location of
the cleavage site(s)156.

5.7 Complementary Findings
While direct measurements of MHC II protein expression in response to NSP5 expression
were not heavily explored in this thesis, preliminary flow cytometry analysis performed
in our lab showed identical trends in which surface MHC II is downregulated in NSP5expressing DCs (data not shown), complementary to findings obtained via
immunofluorescence microscopy, RT-qPCR, and dual luciferase analyses. A recently
published study identified similar findings, demonstrating that SARS-CoV-2 ORF6
downregulates MHC I in infected cells102. While ORF6 directly inhibits the expression
and function of the Class I transactivator protein, our findings implicate NSP5 as an
indirect inhibitor of CIITA transcription through enhancing HDAC2-mediated
deacetylation at the promoter. Interestingly, it appears that the IFNγ signaling pathway is
targeted at multiple steps by SARS-CoV-2, resulting in downregulation of MHC I and
MHC II via ORF6 and NSP5, respectively, and potentially impairing antigen presentation
to adaptive immune cells.

5.8 HDAC2 Inhibitors as Potential Therapeutics Against
COVID-19
With the advent of vaccines being developed over the past couple of years, we have a
strong preventative measure to limit SARS-CoV-2 spread across the world. Novel
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vaccines have been developed that utilize lipid nanoparticles that encapsulate mRNA
encoding the full-length SARS-CoV-2 S protein, such that delivery of this mRNA
vaccine will allow cells to express this viral protein without the requirement of infections
with viral particles157,158. S protein-expressing cells may then present SARS-CoV-2
antigens in the contexts of MHC II and MHC I to CD4+ and CD8+ T cells, respectively,
thereby mounting potent immune responses against future infections of SARS-CoV-2 by
activating antigen-specific memory T cells and generating S protein-specific
antibodies159,160.
While prophylactic approaches may be the most effective strategies to prevent infections,
they are less helpful in patients already suffering from COVID-19. Clinical studies are
currently testing novel immunotherapeutic drugs or repurposing existing drugs to treat
patients with COVID-19. Our findings potentially identified a novel target to improve
COVID-19 prognosis. Specifically, we demonstrated that SARS-CoV-2 NSP5 targets
HDAC2 to antagonize MHC II expression in primary human pAPCs, with knockdown of
HDAC2 reverting this suppression. Our findings suggest that targeting NSP5 and
HDAC2 may be effective therapeutic approaches against COVID-19. Targeting NSP5
may not only prevent viral replication but may also improve host immune responses and
diminish inflammation. Currently, Pfizer is developing an NSP5 enzymatic inhibitor as a
treatment against COVID-19161,162. While helpful in preventing SARS-CoV-2 replication
and attenuating inflammatory responses, our data suggests that the proteolytic activity of
NSP5 is not required for impairing adaptive immune responses, therefore it is unclear if
this therapeutic agent would reverse the suppression of MHC II expression or reverse
other NSP5-HDAC2 mediated events. It can be argued that an HDAC2 inhibitor may be
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a more effective therapeutic agent against COVID-19. Critically, targeting host proteins
rather than viral proteins would reduce the likelihood of SARS-CoV-2 evolving
resistance to the treatment. Additionally, inhibiting HDAC2 can prevent SARS-CoV-2
access to the MHC II transcriptional machinery and restore reduced levels of CIITA and
MHC II, thereby increasing T cell-mediated responses to eliminate the pathogen. In other
diseases, including cancers and neurological disorders, treatment with HDAC inhibitors
such as Trichostatin A and Panobinostat have been shown to increase expression of MHC
II and co-stimulatory molecules through upregulating CIITA and ameliorating CIITA
recruitment to RFX5, leading to an increased capacity to activate T cell responses22,163–
165

. Finally, HDAC2 inhibitors may have additional beneficial effects for patients with

COVID-19, as these drugs have been shown to limit viral entry via reduced ACE2
expression, and they have been proposed to reduce both lung fibrosis and intensity of the
cytokine storm148,166–168.

5.9 Conclusion
Understanding the signaling and vesicular trafficking pathways that dictate antigen
presentation on MHC II is an important step in understanding how different pathogens,
including SARS-CoV-2, can infect and manipulate host immune responses. By studying
the components responsible for regulating these pathways, we can explore how we can
protect ourselves and improve our survival against these pathogens. While it remains
unclear how MHC II is transported from the Golgi to the MIIC, our data suggests that
Rab6 and ERC1 may be facilitating this process via the canonical Golgi export pathway.
Ultimately, our findings may identify a novel trafficking pathway for MHC II that will

88

provide deeper insights into the development of CD4+ T cell-mediated responses against
a multitude of pathogens that hijack components of MHC II regulatory processes to
escape host immune responses. Specifically, understanding how SARS-CoV-2 modulates
antigen presentation is an essential first step to developing effective vaccines and
therapeutics against COVID-19. This thesis provides mechanistic insight into SARSCoV-2-mediated immunoevasion through antagonizing the MHC II antigen presentation
pathway. Furthermore, our data indicate that SARS-CoV-2 may suppress adaptive
immune responses via targeting HDAC2—a major regulator of IFNγ- and CIITAdependent MHC II expression (Figures 16A-B). Altogether, the findings from this study
may have potentially identified HDAC2 as a novel drug target in our combat against this
deadly disease.
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A)

B)
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Figure 16. Proposed model of NSP5-mediated downregulation of MHC II
transcription.
A) Normal MHC II transcription. IFNγ-induced transcription of MHC II genes is
mediated by CIITA binding to the promoter-proximal MHC II enhanceosome—
consisting of RFX5, CREB, and NF-Y. HDAC2 represses transcription of CIITA and
MHC II through deacetylating these genes’ promoters. B) SARS-CoV-2-controlled MHC
II transcription. SARS-CoV-2 NSP5 interacts with HDAC2 and increases its enzymatic
activity, resulting in hyper-deacetylation of the CIITA and MHC II promoter, severely
suppressing transcription of these genes. Figure prepared in BioRender.
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Appendices
Appendix A. Vector maps of MHC II-HaloTag constructs used in this study.
Maps prepared in SnapGene.
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Appendix B. Vector maps of luciferase reporter constructs used in this study.
Maps prepared in SnapGene.
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Appendix C. Vector maps of NSP5 lentiviral vectors used in this study.
Maps prepared in SnapGene.
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